Summary

Initiate at Buy with a $38 target as cost self-help cushions 2027 margins

InitiationBy Penmark Team
DOWBuy$37.84+25%
Page 1 of 32
Equity research | Initiation of coverage | United States
Materials: Chemicals | Coverage: Initiated | Published 20 November 2026, 08:30 ET
Penmark Team | research@penmarkresearch.com
Dow Inc. (NYSE: DOW)

Initiate at Buy with a $38 target as cost self-help cushions 2027 margins

Rating
Initiation
Buy
12-month target
$37.84
Price, 18 Nov 2026
$30.37
Price return
+24.6%
Total return
+29.2%
Bull case
$50.92
Bear case
$16.20

We initiate on Dow Inc. at Buy with a $37.84 twelve-month target and a 29% total return including the $1.40 dividend, with Low conviction. Dow converts natural-gas liquids into plastics, polyurethanes and silicones at 91 sites. Operating EBITDA (earnings before interest, tax, depreciation, amortisation and one-off items) reaches $6.4bn in FY27E.

  • Retained cost self-help adds $8 a share at mid-cycle (about $4.60 after the slower path to mid-cycle). Transform to Outperform cuts and European closures deliver $1.1bn in FY27E and leave $0.9bn of lasting mid-cycle operating EBITDA.
  • US ethane feedstock cushions the 2027 polyethylene reset. US Gulf Coast crackers running above 90% hold FY27E polyethylene give-back to 4¢/lb versus about 8¢/lb in consensus.
  • Working-capital release restores cash conversion ahead of Path2Zero. Cash conversion rebounds to 87% in FY26E and holds near 75% from FY28E, while Path2Zero (Fort Saskatchewan, Alberta) adds $3.70 a share of net present value (NPV).

What the market is missing. Consensus models $5.5bn of FY27E operating EBITDA and $1.84 of operating earnings per share (EPS), below the third-quarter run-rate despite $1.3bn of guided self-help. We sit 16% and 56% higher.

Catalysts. Late-2026 polyethylene contract settlements (+12¢/lb nominated), the FY27 bridge at fourth-quarter 2026 results in late January 2027, Sadara talks and European shutdowns test our call.

Valuation and target. We value Dow at 6.75x mid-cycle operating EBITDA of $7.6bn, add $2.7bn for Path2Zero and deduct $25.3bn of debt and other claims. That gives a base value of about $40 a share. Weighting the bull, base and bear cases gives $36 today, which rolls forward to our $37.84 target. A one-point rise in the weighted average cost of capital (WACC) would make it a Hold.

Risks. A reset to FY23–FY25 trough margins cuts value by $16 a share, lost self-help costs $7, and a Middle East oil unwind costs $1.30.

Exhibit 1: Operating EBITDA recovers to $6.4bn in FY27E, putting Dow on 10.6x P/E and 7.1x EV/EBITDA
Dec YE, $mFY24AFY25AFY26EFY27EFY28E
Net sales42,96439,96844,03343,11543,977
Growth y/y−3.7%−7.0%+10.2%−2.1%+2.0%
Operating EBITDA5,4823,2566,2886,4346,817
Margin12.8%8.1%14.3%14.9%15.5%
Operating net income1,206−6621,9672,0722,399
Operating EPS ($)1.71−0.932.712.873.44
Growth y/y−23.7%n.m.n.m.+5.9%+20.0%
Free cash flow−26−1,4172,9621,9682,398
At $30.37, 18 Nov 26FY24AFY25AFY26EFY27EFY28E
Price / earnings (P/E)17.8xn.m.11.2x10.6x8.8x
EV / Op. EBITDA8.3x13.9x7.2x7.1x6.7x
Price / book (P/B)1.2x1.4x1.4x1.3x1.3x
Free cash flow (FCF) yield−0.1%−6.6%13.4%9.0%11.3%
Dividend yield9.2%6.9%4.6%4.6%4.6%
Return on equity (ROE)6.7%−4.0%12.2%12.6%14.4%
Net debt / Op. EBITDA2.6x4.4x2.1x2.0x1.9x
P/E at our target22.1xn.m.14.0x13.2x11.0x

Source: Company filings; Penmark Research model. Right: multiples at the 18 Nov 2026 close ($30.37; diluted market cap $22,091m; full-bridge EV $45,389m excluding the recovery-path charge, which is the present value of the after-tax profit shortfall below mid-cycle, 4Q26E to FY30E); only the final row is at our $37.84 target. Shaded columns are estimates (E); n.m. = not meaningful.

Base value is about $40 a share (+31%), but bear-case downside outweighs base-case upside

Exhibit 3: Weighted value of $36 rolls forward to our $38 target
$10$20$30$40$50$60Jan-26Jul-26Jan-27Jul-27ActualEstimatesPrice $30.37Bull $53 (+76%)Base $42 (+37%)Bear $17 (−44%)Target $38 (+25%)

Source: Company filings; Yahoo Finance; Penmark Research model. Fan endpoints show 12m rolled values ($53.35 / $41.68 / $16.97).

Scenarios and price target basis
Bull$50.92+67.7%20% prob.

Oct/Nov polyethylene (PE) hikes hold; 100% self-help ($8.6bn normalised EBITDA) at 6.75x; Sadara settles at $1.0bn.

Base$39.78+31.0%55% prob.

PE fades 4¢/lb in FY27E; 85% self-help and 50% Transform to Outperform (T2O) kept ($7.6bn EBITDA) at 6.75x plus Path2Zero.

Bear$16.20−46.7%25% prob.

FY23–FY25 trough margin (11.0%) becomes mid-cycle ($5.2bn EBITDA); self-help competed away; Sadara called.

12m target (rolled from $36.11)$37.84+29.2% total return = Buy (Low conv.)
Upside / downside0.66x+$9.41 base / −$14.17 bear
Exhibit 4: Operating net income recovers to $2.4bn by FY28E
Income statement, $mFY24AFY25AFY26EFY27EFY28E
Net sales42,96439,96844,03343,11543,977
Operating EBITDA5,4823,2566,2886,4346,817
Operating EBITDA margin12.8%8.1%14.3%14.9%15.5%
Depreciation & amort.−2,894−2,834−2,719−2,726−2,717
Operating EBIT2,5884223,5693,7074,100
Net interest expense−611−713−670−667−640
Operating tax & NCI−771−371−932−969−1,061
Operating net income1,206−6621,9672,0722,399
GAAP net income to Dow1,116−2,6239821,6232,282
Exhibit 5: Free cash flow turns positive at $3.0bn in FY26E
Cash flow, $mFY24AFY25AFY26EFY27EFY28E
Operating EBITDA5,4823,2566,2886,4346,817
Working capital, tax & int.−2,568−2,194−825−1,815−1,669
Operating cash flow2,9141,0625,4634,6185,148
Capital expenditures−2,940−2,479−2,501−2,650−2,750
Free cash flow−26−1,4172,9621,9682,398
Dividends to Dow & NCI−1,966−1,490−1,315−1,316−1,310
Share buybacks−49400−230−1,088
Net borrowing & other financing1,6884,534−1,330−1,2550
Change in cash−7981,627317−8330
Exhibit 6: Net debt drops by $1.6bn from FY25A to $12.8bn in FY27E
Balance sheet, $mFY24AFY25AFY26EFY27EFY28E
Cash and equivalents2,1893,8164,1333,3003,300
Trade working capital6,4537,2067,5147,5457,696
Net property (PP&E)22,00422,25022,42822,49922,661
Goodwill & intangibles10,2869,4649,2239,0768,946
Net invested assets38,81940,37739,37038,49238,675
Gross debt16,34318,16117,33916,08416,084
Net debt14,15414,34513,20612,78412,784
Stockholders’ equity17,35516,00816,23416,61116,795
Exhibit 7: Buybacks trim diluted shares to 696m by FY28E
Per share & KPIsFY24AFY25AFY26EFY27EFY28E
Diluted shares (m)705.1711.6725.5721.8696.4
Operating EPS ($)1.71−0.932.712.873.44
GAAP diluted EPS ($)1.57−3.701.352.253.28
Dividend per share ($)2.802.101.401.401.40
FCF per share ($)−0.04−1.994.082.733.44
Book value per share ($)24.6122.5022.3823.0124.12
P&SP Op. EBITDA ($m)3,8562,2664,2634,107n.a.
Cash conversion (%)53.2%32.6%86.9%71.8%75.5%

Source: Company Form 10-K and 10-Q filings; Penmark Research model. Shaded columns are estimates (E); n.a. = not available or not modelled separately after FY27E. Operating EBITDA and operating net income exclude restructuring, impairment and litigation charges; noncontrolling interests (NCI) and postretirement obligations are deducted separately in our equity bridge.

Margins recover to about 15% by FY28E; our FY27E EPS is 56% above the Street

Exhibit 8: Operating EBITDA margin rebounds 7pp from FY25A trough
Growth, margins (%)FY24AFY25AFY26EFY27EFY28E
Growth y/y
Net sales−3.7%−7.0%+10.2%−2.1%+2.0%
Operating EBITDA+1.7%−40.6%+93.1%+2.3%+6.0%
Operating EBIT−6.8%−83.7%+746%+3.9%+10.6%
Operating EPS−23.7%n.m.n.m.+5.9%+20.0%
Dividend per share0.0%−25.0%−33.3%0.0%0.0%
Margins and coverage
Cash conversion53.2%32.6%86.9%71.8%75.5%
Operating EBITDA margin12.8%8.1%14.3%14.9%15.5%
Operating EBIT margin6.0%1.1%8.1%8.6%9.3%
FCF margin−0.1%−3.5%6.7%4.6%5.5%
Op. EBITDA / net interest9.0x4.6x9.4x9.6x10.7x
Capex / net sales6.8%6.2%5.7%6.1%6.3%
Exhibit 9: Operating ROE reaches 14% by FY28E as P/E falls to 8.8x
Ratios and valuationFY24AFY25AFY26EFY27EFY28E
Returns and leverage
Operating ROE6.7%−4.0%12.2%12.6%14.4%
Operating ROA (net assets)3.1%−1.7%4.9%5.3%6.2%
After-tax operating ROIC6.3%1.0%9.0%9.4%10.3%
Net debt / equity81.6%89.6%81.3%77.0%76.1%
Net debt / Op. EBITDA2.6x4.4x2.1x2.0x1.9x
Valuation at $30.37 (18 Nov 2026)
P/E17.8xn.m.11.2x10.6x8.8x
EV / Op. EBITDA8.3x13.9x7.2x7.1x6.7x
P/B1.2x1.4x1.4x1.3x1.3x
FCF yield−0.1%−6.6%13.4%9.0%11.3%
Dividend yield9.2%6.9%4.6%4.6%4.6%
P/E at our target22.1xn.m.14.0x13.2x11.0x

Source: Company filings; Penmark Research model. Operating return on equity (ROE), return on net invested assets (ROA) and return on invested capital (ROIC, equivalent to after-tax return on capital employed, ROCE) use operating earnings; definitions on page 31. Multiples at $30.37 except the final row.

Exhibit 10: We sit 16% above consensus FY27E EBITDA and 56% on EPS
Penmark vs Street4Q26EFY26EFY27EFY28E
Net sales ($m)
Penmark estimate10,88044,03343,11543,977
Consensus10,73343,88643,027n.a.
Prior-year period9,46039,96844,03343,115
Diff. vs consensus+1.4%+0.3%+0.2%n.a.
Growth y/y (Penmark)+15.0%+10.2%−2.1%+2.0%
Operating EBITDA ($m)
Penmark estimate1,5506,2886,4346,817
Consensus1,5586,2965,5485,731
Prior-year period7413,2566,2886,434
Diff. vs consensus−0.5%−0.1%+16.0%+19.0%
Growth y/y (Penmark)+109.2%+93.1%+2.3%+6.0%
Operating EPS ($)
Penmark estimate0.682.712.873.44
Consensus0.562.581.84n.a.
Prior-year period−0.34−0.932.712.87
Diff. vs consensus+20.7%+5.1%+56.0%n.a.
Growth y/y (Penmark)n.m.n.m.+5.9%+20.0%

Source: S&P Global consensus post-3Q26; Penmark Research model. 4Q26E consensus derived as FY26E mean less reported 9M26A; n.a. = not available.

Exhibit 11: Operating EBITDA reaches $6.8bn in FY28E, 19% above FY28E consensus
Consensus$0bn$2bn$4bn$6bn$8bnFY23AFY24AFY25AFY26EFY27EFY28EActualEstimates$5.4bn$5.5bn$3.3bn$6.3bn$6.4bn$6.8bn

Source: Company filings (A); S&P Global consensus; Penmark Research estimates (E).

Why the FY27E gap opens. Consensus matches us on FY26E ($6.3bn) and FY27E revenue ($43.0bn vs $43.1bn), yet cuts FY27E operating EBITDA by $0.7bn. That implies either an 8¢/lb polyethylene margin collapse or just 17% realisation of management’s $1.3bn self-help bridge. We model a 4¢/lb margin fade and 85% ($1.1bn) self-help delivery.

Dow trades about 16% below peers on trailing EV/EBITDA and below its three-year P/B average

Exhibit 12: Dow trades at a 16% EV/EBITDA discount to peers
Snapshot (Sep/Nov 26)DOWPeersDiff.
Valuation at current prices
Trailing EV / EBITDA8.28x9.84x−15.8%
Forward P/E (consensus)16.56x15.82x+4.7%
Trailing EV / sales1.07x0.97x+9.8%
Trailing P/B1.36x1.29x+5.4%
Dividend yield4.6%3.8%+0.8pp
Cycle anchor, margins and balance sheet
Through-cycle EV / EBITDA6.86x6.74x+1.8%
Operating margin (9M / LTM)8.1%5.0%+3.1pp
After-tax ROIC (FY27E vs LTM)9.4%6.8%+2.6pp
Trailing ROE−3.2%2.6%−5.8pp
Net debt / EBITDA2.45x4.94x−2.49x
Market value ($bn)22.097.48+195.3%

Source: 3Q26 peer filings (LYB, WLK, EMN, CE, HUN); Yahoo Finance Nov 2026 for forward P/E, P/B, ROE and yield; Penmark Research model. Dow trailing EV/EBITDA uses full-bridge EV ($45,389m); peers and the 6.86x/6.74x cycle medians use simple EV. Dow FY27E ROIC is shown against peers’ trailing ROIC.

Exhibit 13: Four dated catalysts test margins and self-help over 12m
  • Nov–Dec 26Oct (+7¢/lb) and Nov (+5¢/lb) polyethylene settlements; full hold adds +$0.86/sh vs our 1¢/lb base.
  • Late Jan 274Q26 results and FY27 bridge: we model $1.55bn 4Q EBITDA vs $1.5bn guide and $1.1bn FY27 self-help.
  • 1H 2027Sadara strategic review update with Saudi Aramco; exit at $1.0bn vs $1.3bn carried adds +$0.35/sh.
  • Mid-2027Pending European shutdowns (Böhlen, Schkopau; Barry shut in 2Q26) toward $0.2bn run-rate uplift.

Source: Company 3Q26 earnings release and call; Penmark Research model.

Exhibit 14: Overcapacity (−$16) and lost self-help (−$7) lead downside risks
  • New PE capacity makes trough structural. China additions cap mid-cycle margins at 11.0% ($5.2bn EBITDA). Prob. 40%; −$16.04/sh.
  • Self-help competed away in oversupply. FY27E realisation drops from 85% to 55% (−$0.4bn EBITDA) and mid-cycle retention falls to 0%. Prob. 30%; −$6.61/sh.
  • Middle East de-escalation resets PE spreads. Oil-to-gas spread unwinds by 6¢/lb (−$1.2bn FY27E EBITDA). Prob. 35%; −$1.29/sh.
  • Upside risk: higher T2O delivery & retention. Full FY27E delivery plus 75% mid-cycle productivity retention lift value. Prob. 45%; +$3.30/sh.
Thesis broken if: 2027 self-help tracks below 55% or 10y US Treasury yields lift WACC +1pt (target $26.93, Hold) or levered beta to high end ($24.31, Sell).

Source: Penmark Research model.

Exhibit 15: Trailing P/B averaged 1.6x over three years; spot 1.4x sits 0.5 SD below mean
0.5x1.0x1.5x2.0x2.5x4Q232Q244Q242Q254Q252Q26Mean 1.59x+1 SD 2.07x−1 SD 1.11x1.24x, −0.7 SD

Source: Company filings, 4Q23–3Q26; spot 1.36x (−0.5 SD) at $30.37 on 18 Nov 2026. Standard deviation (SD) bands measure spread around the 1.59x mean (±2 SD = 0.63x–2.55x).

Exhibit 16: Global peers add 0.3x P/B per 10pp ROE; Dow sits at 1.4x
0.5x1.0x1.5x2.0x−10%−5%0%5%10%15%Price / bookTrailing ROEDOWLYBEMNSumitomoCEBASFArkemaSABICHUNWLKWackerR² 0.27, n=10

Source: Yahoo Finance global chemical snapshot (incl. uncovered BASF, SABIC, Arkema, Wacker, Sumitomo), Nov 2026; R-squared (R²) = share of P/B variance explained.

PART 1 · SUMMARY · 3 THE THESIS IN CHARTS

Six charts trace our Buy call from earnings to a base value of about $40

Dow’s market value tracks operating EBITDA across the cycle, and Street estimates miss the 2027 cost bridge. Retained self-help and Path2Zero lift base value $9 above the $30 share price, though discount-rate sensitivity caps conviction.

Exhibit 17: Year-end market cap tracks operating EBITDA (0.64 correlation)
Operating EBITDAYear-end market cap (right)$0.0bn$2.5bn$5.0bn$7.5bn$10.0bn$12.5bn$10bn$20bn$30bn$40bn$50bnFY19AFY20AFY21AFY22AFY23AFY24AFY25A

Source: Company filings and year-end market cap, FY19A–FY25A.

Exhibit 18: $1.1bn of 2027 self-help offsets a $0.8bn PE margin reset
$0m$2,000m$4,000m$6,000m$8,000mFY26EOp. EBITDAPEmargin (−4¢/lb)2027self-help (85%)P&SPvolume (+2%)II&I MDInormaliseCorporate& otherFY27EOp. EBITDA$6,288m−$800m+$1,105m+$92m−$240m−$11m$6,434m

Source: Penmark Research model FY26E–FY27E bridge.

Exhibit 19: $2.87 FY27E operating EPS sits 56% above $1.84 Street mean
Street rangeConsensus meanPenmark$1.0$1.5$2.0$2.5$3.0FY26EFY27E$2.71, +5%$2.87, +56%

Source: S&P Global and Yahoo Finance broker range; Penmark Research.

Exhibit 20: At $30.37, EV/EBITDA drops to 7.1x in FY27E near 6.9x mean
4x6x8x10xFY19AFY21AFY23AFY25AFY27EActualEstimates6.7xCycle mean 6.86x

Source: Company filings (A; simple EV); Penmark Research model at $30.37 (E; full-bridge EV $45,389m).

Exhibit 21: Self-help (+$8) and Path2Zero (+$4) drive the $9 value gap
Self-help held atmid-cycleAlberta Path2Zero NPVSadara capped at bookThrough-cycle marginanchorRecovery-path PV charge+$8.05+$3.70+$0.40+$0.04−$2.77

Source: Penmark Research model ($30.37 share price to $39.78 base value).

Exhibit 22: Base value is $40; +1pt WACC ($27) or high beta ($24) flips call
Primary 6.75x (bear–bull)Full-cycle DCF (bear–bull)Target at WACC ±1ptTarget across beta range$0$20$40$60$80$16$51$14$76$27$54$24$46Price $30Target $38

Source: Penmark Research model.

Synthesis for the rating. At $30.37, the market prices 5.9x normalised operating EBITDA (or a 9.4% WACC), giving almost zero lasting credit to Transform to Outperform or Path2Zero. Because $25.3bn of debt and non-debt claims sit ahead of equity, small shifts in WACC or beta swing equity value sharply. That sensitivity keeps conviction Low.
PART 1 · SUMMARY · 4 KEY DEBATES

Value debates explain the $9 gap between the $30 share price and our $40 base value

Three value debates drive our $9.41 gap above the share price, while polyethylene margins explain our FY27E earnings gap versus consensus. Each debate maps to a thesis chapter and resolves across five dated checkpoints through October 2027.

Exhibit 23: We take the other side of the market on self-help, 2027 PE spreads and Path2Zero
Debate Market view Penmark view Independent evidence What changes our view Resolves
Self-help durability Cost cuts are competed away; FY27E Street implies 17% realisation (~$220m) and zero mid-cycle credit. 85% of FY27E guide ($1,105m) and 50% productivity held ($867m mid-cycle credit, +$8.05/sh). FY25 savings beat $300m guide at $400m+; FY26 T2O raised from $500m to $700m; 9M26 severance $481m booked. FY27 bridge realisation falls below 55% or SG&A/cost per ton rebounds with inflation. Jan–Oct 27
Polyethylene margin floor Middle East normalisation and China supply cut FY27E PE margins ~8.4¢/lb ($5.5bn EBITDA). US ethane holds reset to −4.0¢/lb (−$800m), lifting FY27E EBITDA to $6.4bn (+$886m vs Street). US Gulf Coast crackers run above 90% vs low 80s global; US ethane near 27¢/gal; Sep +5¢/lb hike settled. US integrated PE contracts drop >8¢/lb in 1H27 or global operating rates slip below 80%. Dec 26–Jul 27
Path2Zero optionality At 5.9x implied EV/EBITDA, market prices Path2Zero capex drag with zero net NPV. $1.0bn run-rate EBITDA plus $0.9bn incentives PV yields $2.7bn (+$3.70/sh) net value. Project ~45% complete; Phase 1 end-2029, Phase 2 2030; two $650m cash incentives assumed FY31E–32E. Remaining capex ($4.1bn) overruns >20% (~$8.3bn total) or start-up slips past 2031. Mid 27–29
Sadara & legacy claims Bears fear $1.55bn guarantee call; headline screens omit $11.9bn non-debt claims and wait cost. Deduct $1,258m Sadara book liability (+$0.40/sh vs call) and −$2.77/sh recovery-path drag. 10-Q Notes 9 & 19 carry $758m negative investment + $500m guarantee; cash funding falls ~$100m/yr. Aramco JV restructuring triggers >$1.3bn cash call, or settlement below $1.0bn adds upside. 1H 2027

Source: Company 10-Q/8-K filings and 3Q26 call; S&P Global consensus; Penmark Research model.

Exhibit 24: Self-help (+$8) and Path2Zero (+$4) bridge $30 to $40
Market viewPenmark baseSelf-help creditPath2Zero valueSadara & marginRecovery path$31.74$39.78$36.08$39.78$39.35$39.78$39.78$42.56

Source: Penmark Research model (base-value bridge from $30.37 to $39.78).

How the debates map to our thesis

Three thesis chapters quantify our value bridge and FY27E earnings gap. Our value bridge adds self-help (+$8.05), Path2Zero (+$3.70), Sadara (+$0.40) and margin (+$0.04), less the −$2.77 recovery-path wait cost (present value of the after-tax profit shortfall below mid-cycle, 4Q26E to FY30E). Separately, polyethylene margins drive our +$886m FY27E EBITDA edge over consensus.

Why the market gets 2027 wrong

Consensus double-counts the margin fade while ignoring structural plant exits. Brokers extrapolate mid-2026 polyethylene weakness into FY27E ($5.5bn EBITDA) without crediting permanent fixed-cost removal at Barry (shut 2Q26), Böhlen and Schkopau or 4,500 T2O role reductions.

Exhibit 25: Five dated events through October 2027 test every pillar of our Buy call
Dec 2026Oct/Nov PE settlements+12¢/lb nominated; baseassumes −4¢/lb in FY27ELate Jan 20274Q26 results & FY27bridgeTests $1.3bn self-helpguide vs $1.1bn base1H 20271Q27 print & SadarareviewAramco JV negotiation vs$1,258m book liabilityMid 20272Q27 print & EU closuresBöhlen & Schkopaushutdown progress;Path2Zero capexOct 20273Q27 operating rate testGlobal ethylene rates vslow-80s baseline

Source: Company calendar; industry contract schedule; Penmark Research.

PART 2 · THE BUSINESS · 5 THE STORY

After the 2025 trough, we credit about $0.9bn of Dow’s cost cuts as lasting

Dow turns cheap American natural-gas liquids into everyday food packaging, insulation foams and silicone sealants across 91 plants. Investors still price a commodity treadmill just as European plant closures and cost cuts reshape its mid-cycle earnings floor.

1897Founded in Midland, MI
29 countriesGlobal footprint
91 sitesManufacturing plants
34,600Employees (FY25 10-K)
$40.0bnFY25A net sales
$22.1bnMarket cap, 18 Nov 26

The scene

On the US Gulf Coast in the third quarter of 2026, Dow’s gas-fed furnaces ran above 90% capacity while the global ethylene industry ran in the low 80s. That feedstock gap let Dow lift Packaging & Specialty Plastics local prices 17% year on year and segment volume 1%, even as total Dow volume dipped 1%. Spun out of DowDuPont in April 2019, Dow supplies manufacturers across packaging, infrastructure, mobility and personal care.

What it actually does

Dow cracks ethane and propane from natural gas, alongside naphtha from crude oil, into ethylene and propylene molecules. It then links those molecules into polyethylene pellets for food wrap, polyurethane foams for home insulation, and silicone rubbers for electronics and coatings.

Why it works, and why it might not

Converters stay with Dow for multi-year food-contact qualifications and reliable Gulf Coast supply. The loop breaks if Chinese overcapacity forces Dow to hand its cost cuts back in lower resin prices, linking directly to self-help durability and the polyethylene margin floor.

How the money comes in

Product shipments generate 97% of Dow’s $40.0bn FY25A sales, billed per pound or metric ton on monthly contracts and spot orders. Packaging & Specialty Plastics contributes 50% of revenue ($20.0bn), Industrial Intermediates & Infrastructure 28% ($11.2bn), and Performance Materials & Coatings 20% ($8.1bn). Each 1¢/lb move in integrated polyethylene margin swings annual operating EBITDA by $200m; in FY26E, $1.00 of sales leaves 14.3¢ of operating EBITDA and 6.7¢ of free cash flow.

Where the story turns

After operating EBITDA peaked at $12.4bn in FY21A, Chinese plant startups and European energy costs crushed FY25A operating EBITDA to $3.3bn. Management halved the dividend to $0.35 a quarter in July 2025, shut Barry in 2Q26, slated Böhlen and Schkopau for closure, launched the $2.0bn Transform to Outperform overhaul, and named 30-year veteran Karen S. Carter chief executive officer (CEO) on 1 July 2026.

$867mRetained mid-cycle EBITDA
We credit half of Transform to Outperform’s productivity cuts ($0.7bn) plus $0.2bn from European plant exits at mid-cycle.Source: Company 3Q26 release; Penmark Research model. Worth +$8.05 per share against consensus zero credit.
1 · FEEDSTOCK ADVANTAGE
~27¢/galUS Gulf Coast ethane near 5y average; crackers run above 90%.
2 · PRODUCT SHIPPED
97% goodsResin pellets, MDI systems and silicones from 91 plants.
3 · CONTRACT BILLING
$200m / 1¢Monthly resin contracts; $199m deferred revenue at Sep-26.
4 · WHAT DOW KEEPS
14.3¢ / $1FY26E operating EBITDA margin; 6.7¢ converts to free cash flow.

Source: FY25 Form 10-K, 3Q26 Form 8-K and call, Penmark Research model.

Why the story matters for the stock. At $30.37, the market prices Dow at 5.9x normalised operating EBITDA as if none of the 2025–2027 restructuring sticks. Our first thesis chapter argues why $0.9bn of assumed structural cost and closure gains endure.
PART 2 · THE BUSINESS · 5 HOW THE COMPANY MAKES MONEY

Packaging & Specialty Plastics is half of FY25 sales and about 70% of operating EBITDA

Exhibit 26: Two restructuring turns since the 2019 spin reshaped Dow’s $40.0bn platform
1897
Founded in MidlandHerbert Dow extracts bromine from Michigan brine, later adding chlorine.Midland HQ
2017
DowDuPont mergerMerges with DuPont to split into materials, ag and specialty units.3-way split plan
Apr 2019
Standalone NYSE spinSpins off as focused materials-science producer on 1 April 2019.$43.0bn FY19 sales
FY21
Post-COVID peakTight resin supply lifts operating EBITDA margin to cycle high.$12.4bn EBITDA (23%)
Nov 2023
Path2Zero approvedApproves Fort Saskatchewan net-zero ethane cracker in Alberta.$1.0bn run-rate target
Jul–Aug 25
EU exits & div. cutSlates 3 EU plants for closure and halves quarterly dividend.$0.35/qtr; $3.3bn EBITDA
2026
Carter CEO & T2OKaren Carter named CEO (Jul 26); T2O targets $2.0bn uplift by 2027.$44.0bn FY26E sales
Turning pointMilestoneToday

Source: Company Form 10-K, DEF 14A and 3Q26 release; Penmark Research model.

Exhibit 27: Six-stage business model map: $40.0bn of FY25A sales yield $3.3bn of trough operating EBITDA
1 · END MARKETS 2 · SEGMENTS 3 · BUSINESSES (FY25A) 4 · REGIONS & SITES 5 · COST TO SERVE 6 · WHAT IS LEFT Packaging Food film, pouches, caps, Stretch wrap Resilient GDP+ vol. Infrastructure Insulation, pipes, coatings (40% MDI) Rate-sensitive Consumer & Auto Personal care, EV thermal, appliances 97% product sales P&SP $19,970m (50.0%) −8.3% y/y FY25A Op. EBITDA $2,266m 11.3% margin (67% of segment EBITDA) FY26E: $4,263m II&I $11,163m (27.9%) Op. EBITDA $61m FY26E: $986m PM&C (+Corp $701m) $8,134m (20.4%) Op. EBITDA $1,046m 12.9% margin Packaging & Spec. Plastics $14,594m (36.5%) PE resins, elastomers Hydrocarbons & Energy $5,376m (13.5%) Polyurethanes & Const. $7,110m (17.8%) Ind. Solutions $4,036m Consumer Solutions $4,919m (12.3%) Coatings $3,215m (8.0%) US & Canada $15,806m (39.5%) 32 sites; low-cost ethane >90% util. EMEAI $12,589m (31.5%) 31 sites; 1 shut, 2 closing Asia Pac $7,219m 18.1% · 15 sites LatAm $4,354m (10.9%) Cost of sales $37,435m GAAP (93.7% of FY25 sales) NGLs, naphtha, energy, plant labor D&A: $2,834m R&D+SG&A $2,144m Op. EBITDA $3,256m (8.1%) FY26E Recovery Sales $44,033m EBITDA $6,288m 14.3% margin FCF +$2,962m 6.7% FCF margin CFO $5,463m FY25A Trough Op. EBIT $422m CFO $1,062m Capex −$2,479m FCF −$1,417m Div. paid −$1,490m GAAP NI −$2,623m (incl. restructuring)
$39,968mFY25A net sales (−7.0% y/y)
+14.0% y/y3Q26 local price & mix
−1.0% y/y3Q26 volume growth
83% / >90%3Q26 H&E global / USGC rate
86.9%FY26E CFO / Op. EBITDA

Source: FY25 Form 10-K segment and geographic notes; Penmark Research model for FY26E recovery panel. P&SP accounts for 70% of consolidated operating EBITDA (including Corporate) and 67% of the three-segment sum.

Feedstock integration sets Dow’s margin floor. Because Hydrocarbons & Energy crackers supply internal ethylene to Packaging & Specialty Plastics, low-cost US ethane turns oil-linked global polyethylene hikes directly into operating EBITDA.

Operating leverage works fast in both directions. With $2.8bn of annual depreciation and high fixed plant costs, a 6.1pp margin rebound from FY25A (8.1%) to FY26E (14.3%) swings free cash flow by $4.4bn (−$1.4bn to +$3.0bn).

PART 2 · THE BUSINESS · 5 PRICING, SEGMENTS AND COST STRUCTURE

Cash costs take 86% of sales, so small moves in resin spreads swing profits

Dow buys natural-gas liquids at North American gas-linked prices and sells plastics and intermediates at global oil-linked contract prices. Because plant staffing, maintenance and depreciation are largely fixed once crackers run, small price-over-feedstock shifts flow straight to operating EBITDA.

Exhibit 28: Packaging & Specialty Plastics supplies 52% of FY26E sales ($22.9bn) and 68% of operating EBITDA ($4.3bn)
P&SP sales$22,882mII&I sales$11,700mPM&C sales$8,741mCorporate$710mNet sales$44,033mOperating EBITDA$6,288mCash operating costs$37,745mD&A$2,719mOperating EBIT$3,569m

Source: Penmark Research model, FY26E revenue-to-operating-EBIT flow.

Exhibit 29: P&SP earns a 19% FY26E EBITDA margin versus 8% in II&I and 13% in PM&C
Segment FY25A
Sales ($m)
FY26E
Sales ($m)
FY26E
EBITDA
FY26E
Margin
What it sells & why customers buy Pricing & feedstock driver
Packaging & Specialty Plastics (P&SP) 19,970 22,882 4,263 18.6% LLDPE/LDPE/HDPE food packaging resins ($14.6bn FY25), functional polymers, ethylene/propylene ($5.4bn). Monthly contract indices (CDI/Argus); US ethane (~27¢/gal) vs global oil-linked naphtha ($200m per 1¢/lb).
Industrial Intermediates & Infra. (II&I) 11,163 11,700 986 8.4% Polyurethane systems & MDI ($7.1bn FY25) for appliance/building insulation; EO/PO alkoxylates & solvents ($4.0bn). 40% housing-exposed; benzene, propylene and chlorine inputs; Sadara & EQUATE Middle East JVs.
Performance Materials & Coatings (PM&C) 8,134 8,741 1,148 13.1% Silicone elastomers & sealants ($4.9bn FY25) for electronics/personal care; architectural acrylic binders ($3.2bn). Downstream formulation pricing sticky; upstream siloxane monomer pressured by China supply (Barry shut 2Q26).
Corporate 701 710 −109 n.m. Captive insurance, financing and unallocated enterprise services. Directly reduced by Transform to Outperform SG&A and role cuts.
Consolidated Dow 39,968 44,033 6,288 14.3% 97% physical product sales across 91 sites in 29 countries. Volume × local price/mix less hydrocarbon & energy cash cost.

Source: FY25 Form 10-K Note 24 segment disclosures; Penmark Research model.

Pricing, billing and customer stickiness

Resin prices reset monthly, whereas downstream formulations reset quarterly or annually. In P&SP, North American converters buy on monthly negotiated contracts benchmarked to trade indices; in Consumer Solutions silicones, qualification into cosmetics, semiconductors and electric-vehicle batteries creates multi-year switching costs. Customer prepayments are negligible, with deferred revenue of just $199m at 30 September 2026.

Fixed versus variable cost leverage

Variable hydrocarbon feedstock and fuel inputs dominate cost of sales ($37.4bn in FY25A), while crackers carry steep fixed-cost thresholds. Steam crackers must run above 85% utilisation to absorb maintenance, labour and $2.8bn of annual depreciation. Shutting Barry siloxanes (completed 2Q26) and pending closures at Böhlen and Schkopau remove $0.2bn a year of structural drag by 2029.

What this means for our forecast. Because P&SP generates two-thirds of segment EBITDA (67% of the FY25A segment sum), FY27E earnings hinge on whether $1.1bn of self-help (85% of guide) outweighs a 4¢/lb ($0.8bn) polyethylene margin give-back.
PART 2 · THE BUSINESS · 5 DRIVER TREE, REGIONS AND CASH CONVERSION

US & Canada and EMEAI make up 71% of sales; working-capital release lifts FY26E cash conversion

Dow’s revenue equation multiplies shipped tonnage by local price and mix across US & Canada and Europe, Middle East, Africa and India (EMEAI). Highlighted driver-tree nodes mark two confirmed stock drivers, integrated polyethylene spreads and Transform to Outperform cost self-help, alongside P&SP volume. Our third confirmed driver (cash conversion and dividend cover) is detailed in Exhibit 32.

Exhibit 30: FY26E net sales of $44.0bn (+10% y/y) rest on integrated PE spreads, MDI recovery and silicones
Integrated PE margin$200m EBITDA per 1¢/lbP&SP volume & JVs+2.0% FY27E ex-MEP&SP (52% share)$22,882m | EBITDA $4,263mMDI & polyurethanes40% housing-exposedAlkoxylates growth+$60m FY27E EBITDAII&I (27% share)$11,700m | EBITDA $986mDownstream silicones+3.0% FY27E volumeT2O cost self-help+$1,105m (85% of guide)PM&C & Corp (21%)$9,451m | EBITDA $1,039mNet sales FY26E$44,033m (+10.2% y/y)3Q26 P&SP proof pointLocal price +17% y/y;volume +1% y/y;USGC crackers >90%3Q26 II&I proof pointSales $3,058m (+8% y/y);peer MDI outages fadein 4Q26–FY27E (−$300m)3Q26 Self-help proof$700m FY26 T2O uplift(up from $500m guide);$2.0bn target end-2027

Source: Company 3Q26 release and call; Penmark Research model. Blue-shaded boxes mark confirmed stock drivers.

Exhibit 31: North America and EMEAI drive 71% of FY25A sales
$40.0bnFY25A salesUS & Canada39.5%$15.81bnEMEAI31.5%$12.59bnAsia Pacific18.1%$7.22bnLatin America10.9%$4.35bn

Source: FY25 Form 10-K geographic note (91 sites across 29 countries).

Exhibit 32: Working capital & cash conversion ($m)
Cash bridgeFY25A9M26AFY26EFY27E
Operating EBITDA3,2564,7386,2886,434
Cash from operations (CFO)1,0624,2875,4634,618
Cash conversion (%)32.6%90.5%86.9%71.8%
Capital expenditures−2,479−1,841−2,501−2,650
of which Path2Zeron.a.n.a.n.a.−1,150
Free cash flow−1,4172,4462,9621,968
Trade working capital (end)7,2067,6147,5147,545

Source: Company 3Q26 release; Penmark Research model. n.a. = not disclosed separately prior to FY27E.

Profit-to-cash conversion and working capital

Working-capital discipline reversed FY25A’s cash burn. In FY25A, $1.2bn of working-capital outflow and restructuring dragged continuing CFO down to $1.1bn (33% conversion). Releasing over $0.4bn of working capital in 3Q26 (over $0.5bn guided for 2H26) lifted 9M26A conversion to 91%, supporting 72%–76% conversion in FY27E–FY29E even after $0.6bn of FY27E restructuring cash.

Customer, supplier and regional concentration

No single customer exceeds 10% of consolidated revenue, limiting customer concentration risk. Regional exposure is balanced across 32 North American sites, 31 EMEAI sites, 15 Asia Pacific sites and 13 Latin American sites. Key raw-material exposure sits in US Gulf Coast ethane/propane pipelines and Middle East joint-venture feedstocks: EQUATE, The Kuwait Olefins Company (TKOC) and Sadara.

PART 2 · THE BUSINESS · 6 SUPPLY, DEMAND AND GLOBAL ETHYLENE COST CURVE

Global ethylene runs in the low 80s and needs about 10% of capacity to close; US Gulf Coast crackers run above 90%

Commodity chemicals clear on the marginal producer’s cash cost. Published 2025 global polyethylene demand estimates span 118m–129m metric tons (about 43m tons exported across regions), while management estimates post-2021 builds pushed global cracker utilisation into the low 80s.

Exhibit 33: Dow captures integrated margin across three stages from US NGL cracking to specialty resins
NGL & naphthaUS shale gas, Aramco,refinersUS ethane ~25–28¢/galSteam crackingDow (>90% USGC rate),LYB, Exxon$5.4bn H&E sales FY25APolyethylene & monomersDow, SABIC, Sinopec, WLK$14.6bn P&SP resinsFY25ASpecialty formulationsDow silicones/MDI, BASF,Wacker$19.3bn II&I + PM&CFY25AConverters & brandsAmcor, Berry, Sealed Air,CPGs97% product salesDow integrated footprint (91 sites in 29 countries)

Source: FY25 Form 10-K Notes 4 & 24; 3Q26 earnings call; Penmark Research.

Exhibit 34: Dow averaged 15% EBITDA margin over FY19A–25A, beating LYB
Dow Op. EBITDA marginLYB GAAP EBITDA margin0%5%10%15%20%25%FY19AFY20AFY21AFY22AFY23AFY24AFY25A8.1%3.2%

Source: Company filings; LyondellBasell Form 10-K; Penmark Research model.

Exhibit 35: Global ethylene cash-cost ranking & cycle status
Cost quartileFeedstock & region2026 cycle status & Dow exposure
1st quartile (lowest)Middle East ethane (Saudi Arabia, Kuwait, Qatar)Regulated gas pricing; 2026 regional conflict curtailed output (~$160m FY26 drag at Dow’s EQUATE, TKOC and Sadara JVs).
1st / low-2nd quartileUS Gulf Coast & Alberta ethane (Texas, Louisiana, Canada)Shale NGL ethane near 5-yr average (~27¢/gal); US Gulf Coast crackers run above 90% vs global low 80s; Dow’s core profit pool.
3rd quartileAsian naphtha & coal/methanol-to-olefins (MTO/CTO)Oil-linked naphtha and MTO/CTO plants in China and Korea set marginal Asian clearing prices; co-product credits vary.
4th quartile (marginal)European naphtha crackers (Germany, UK, France, Italy)High energy, carbon and age penalties; 5%–6% global closures announced (~8% speculated), including Dow Böhlen & Schkopau.

Source: Industry cost-curve studies; Dow 3Q26 call; Penmark Research.

Bottom-up demand drivers and cycle position

Packaging is resilient, whereas construction and durables remain interest-rate constrained. Industry studies expect global polyethylene demand to expand roughly 3.5%–4.4% a year on food protection, cold-chain e-commerce and emerging-market consumption. By contrast, 40% of methylene diphenyl diisocyanate (MDI) polyurethane demand depends on housing and appliances, where 5.15% 10-year US Treasury yields continue to suppress turnover.

Supply rationalisation, regulation and substitution

Management estimates closing about 10% of global ethylene capacity is required to restore mid-cycle utilisation. With 5%–6% already announced in Europe and Northeast Asia and about 8% speculated, supply discipline is underway. Regulatory plastic-waste mandates, recycled-resin targets and 2025–2026 tariff realignments pose substitution and trade-routing risks, which Dow addresses through mono-material recyclable films and its zero-Scope-1/2 Path2Zero cracker.

Why the market cycle matters for our call. We do not model a return to FY21A’s 23% peak margin. Our base value rests on Dow’s 14.8% FY19A–FY25A historical average plus +1.9pp of assumed self-help.
PART 2 · THE BUSINESS · 7 COMPETITIVE POSITION

US ethane feedstock scale and 5% SAR&D overhead give Dow a durable cost edge over global peers

In bulk chemicals, low-quartile feedstock integration and lean overhead decide survival through troughs. Dow combines top-tier US Gulf Coast and Canadian ethane cracking with specialty silicone and elastomers franchises, while running selling, administrative and research & development (SAR&D) expense at about 5% of sales versus about 12% across chemical peers.

Exhibit 36: Dow pairs $22bn scale with 13% 3Q26 sales growth
12%20%5%10%5%20%Trailing EBITDA margin3Q26 revenue growth (y/y)Circle area: market cap ($bn)Defensive specialtyRebounding & high marginTrough compressedVolume/price reboundDOWLYBWLKEMNCEHUNBASFArkema

Source: Yahoo Finance global chemical peer snapshot (19 Nov 2026; EUR market caps converted at 1.10 USD/EUR); company filings.

Exhibit 37: Advantage scorecard vs LYB, Westlake & BASF
DOWLYBWLKBASFUS ethane cost advantageCracker & derivative scaleOverhead & SAR&D leannessSilicones & specialty mixLiquidity & maturity runwayLow-carbon cracker roadmapNoneWeakFairStrongLeading

Source: Company filings; 3Q26 call (SAR&D 5% vs peer 12%); Penmark assessment.

Exhibit 38: Segment competitors, substitutes, customer choice criteria & Dow’s competitive moat
Segment Primary competitors Substitutes Customer choice criteria Source & durability of Dow’s advantage
Packaging & Specialty Plastics ExxonMobil Chemical, LyondellBasell (LYB), SABIC, Chevron Phillips, Westlake (WLK), Sinopec. Recycled resin (rPE), paperboard, aluminium, glass, bio-polymers. Delivered cost/lb, film dart/seal strength, run-speed on converter lines, low-carbon footprint. Feedstock + catalyst IP: US Gulf Coast crackers above 90%, proprietary octene/ELITE metallocene resins, and Path2Zero zero-Scope-1/2 PE by 2030.
Industrial Intermediates & Infra. Covestro, Wanhua Chemical, BASF, Huntsman (HUN), Shell Chemicals. Mineral wool & fibreglass insulation; bio-based surfactants. Regional supply reliability, formulated polyurethane system specs, purity in pharma/home care. Mixed: Strong North American alkoxylate expansion (+$60m FY27E EBITDA), but commodity MDI trails Wanhua’s scale and carries Sadara JV drag.
Performance Materials & Coatings Wacker Chemie, Shin-Etsu, Elkem, Momentive (silicones); Arkema, Celanese (CE), BASF, Eastman (coatings). Polyurethane/acrylic sealants, epoxy thermal interface materials (TIMs), solvent-borne coatings. OEM spec qualification, thermal/dielectric stability, regulatory & skin-safety compliance. Downstream formulation moat: Shutting upstream Barry siloxanes (2Q26) shifts mix toward sticky electronics, EV thermal and personal-care silicones (+3% vol FY27E).

Source: FY25 Form 10-K; Penmark Research model.

Where Dow wins: cost position and overhead

Dow averaged a 14.8% operating EBITDA margin over FY19A–FY25A, and its 8.1% FY25A trough margin stayed 490bp above LYB’s GAAP margin (3.2%). Benchmarking on the 3Q26 call showed Dow’s SAR&D ratio at about 5% of revenue against 12% for diversified peers, while Transform to Outperform removes about 4,500 roles.

Where peers press Dow: balance sheet and MDI

On a consistent trailing basis, Dow’s 2.45x net debt/EBITDA sits below the 4.94x US peer median (LYB is 1.67x), while Wanhua caps global MDI pricing. Even with manageable leverage, our equity bridge deducts $25.3bn of total claims, covering debt, minority interest, pensions, Sadara, environmental, asbestos, restructuring cash and the recovery-path drag.

PART 2 · THE BUSINESS · 8 MANAGEMENT, GOVERNANCE AND CAPITAL ALLOCATION

New CEO Karen Carter has about 80% of pay at risk, with 30% of her bonus tied to the $2bn transformation

Exhibit 39: Key people panel: FY25 bonuses paid 18% of target; 2026 adds a 30% Transformation weight
Who Tenure & background How they are paid (FY25 Summary Compensation Table [SCT] & 2026) What they own (at $30.37/sh) & Form 4
Karen S. Carter
Chief Executive Officer
NEW CEO · JUL 2026
0.4 yrs as CEO (started Jul 2026); COO from Dec 2024; >30 yrs at Dow; career Dow commercial & P&SP leader. $7.17m FY25 SCT ($6.66m ex-pension: 19% sal/other, 3% bonus, 78% equity). Jul 2026 CEO target: $1.50m salary, 165% bonus, $14.03m LTI + $4.35m promotion LTI.
Bonus: 70% Op. EBIT & FCF, 30% T2O; PSUs on ROC, CFO, TSR.
$11.49m (378,291 sh; <0.1% outst.; 7.7x CEO salary; incl. 325,683 options/units). Jul 2026 CEO grant: 24,150 RSUs + 126,640 derivative shares; zero open-market sales.
Jeffrey L. Tate
Chief Financial Officer
3.1 yrs as CFO (started Oct 2023); prior CFO at Leggett & Platt (2019–23) after earlier Dow finance tenure. $6.08m FY25 SCT ($5.85m ex-pension: 20% sal/other, 3% bonus, 77% equity); FY25 base salary $0.955m, 110% bonus target.
LTI: 65% PSUs (Op. ROC + Cum. CFO), 20% options, 15% RSUs.
$2.83m direct post-Oct Form 4 (93,197 sh; <0.1%; 3.0x salary; Feb proxy 25,017 beneficial sh). 26 Oct 2026 Form 4: 25,564 sh at $33.99 code D to issuer (not market sale).
Jim Fitterling
Executive Chair
NEW ROLE · JUL 2026
0.4 yrs as Exec Chair (Jul 2026 to 2027 AGM); CEO 2018–Jun 2026 (~8 yrs) & Board Chair since 2020; 42 yrs at Dow. $19.08m FY25 SCT ($17.65m ex-pension: 13% sal/other, 3% bonus, 84% equity; compensation actually paid [CAP] −$0.89m on TSR drop).
Metrics: 18% FY25 bonus payout after EBIT/FCF missed threshold.
$63.02m (2,075,141 sh; 0.29% outst.; 37.2x FY25 salary; 290,263 direct + 1,784,878 options/units). Zero open-market selling across 2025–26.
Amy E. Wilson
General Counsel & Corp. Secretary
7.6 yrs in role (started Apr 2019 spin-off); career Dow legal & corporate affairs executive. $4.86m FY25 SCT ($4.37m ex-pension: 26% sal/other, 4% bonus, 70% equity); FY25 base salary $0.880m, 100% bonus target.
Metrics: same 70% financial / 30% T2O bonus & PSU framework.
$16.03m (527,945 sh; <0.1% outst.; 18.2x salary; 65,263 direct + 462,682 options/units). Small code D issuer withholding at $29.90 on 26 Feb 2026.

Source: 2026 DEF 14A (27 Feb 2026; beneficial holdings as of 6 Feb 2026 include options exercisable and units vesting within 60 days); CEO transition Form 8-K (14 Apr 2026) and Form 8-K/A (6 Jul 2026); Form 4 filings through Nov 2026. Note: Former CTO Dr. A.N. Sreeram ($4.74m FY25 SCT; 414,046 sh) stepped down on 31 Dec 2025. Mix bar: grey = salary/other, mid-blue = cash bonus, dark-blue = equity.

Does pay reward per-share value?

Yes: trough payouts collapsed when cash flow missed, and 2026 bonuses lock onto self-help. Roughly 80% of CEO and 74% of named executive officer (NEO) target pay is at risk. In FY25A, annual bonuses paid just 18% of target after Operating EBIT and FCF missed thresholds, and CEO “compensation actually paid” (CAP) was −$0.9m. For 2026, the board set 70% of the annual bonus on Operating EBIT/FCF and 30% on Transform to Outperform (capped at 100% if financial thresholds miss), while 3-year performance share units (PSUs) run on return on capital (ROC), cash flow from operations (CFO) and total shareholder return (TSR). Ownership guidelines (6x CEO salary, 4x NEOs), clawbacks and hedging/pledging bans apply.

Board independence, voting and dilution

Governance is clean, with one-share-one-vote common stock and no controlling holder. Independent Lead Director Richard K. Davis counterbalances Jim Fitterling’s transition Chair role through the 2027 annual meeting. On 3Q26 13F filings, three institutions hold above 5%: Vanguard (12.4%), BlackRock (8.0%) and State Street (5.4%); all 22 directors and officers own 3.9m shares (0.5%). Say-on-pay won 91% support at the April 2026 annual meeting (92% in 2025), while the 2026 stock plan amendment lifted authorised plan shares from 125m to 185m.

Exhibit 40: Of $15.2bn FY26E–FY28E operating cash flow, 52% funds capex and 26% pays dividends
Operating cash flow FY26E–28E$15,229mBase & FY26E Path2Zero capex$5,551mFY27E-28E Path2Zero capex$2,350mCommon & NCI dividends$3,941mNet debt repayment$2,003mBuybacks & other cash$1,384m

Source: Penmark Research model, cumulative FY26E–FY28E operating cash deployment. FY26E capex ($2.5bn) includes Alberta spend; FY27E–28E Path2Zero capex ($2.4bn) is shown separately.

PART 2 · THE BUSINESS · 8 CAPITAL ALLOCATION RECORD AND GUIDANCE CREDIBILITY

Management beat cost-saving targets by 33%–40%, earning partial credit while cycle calls stay discounted

Dow’s track record splits sharply between controllable costs and uncontrollable commodity spreads. Management exceeded FY25 cost savings by $100m (+33%) and raised FY26 Transform to Outperform savings from $500m to $700m (+40%), while quarterly EBITDA guidance split one beat and one miss in 2026.

Exhibit 41: Cost targets beat; quarterly EBITDA was one beat, one miss
FY26 T2O upliftFY25 cost savings1Q26 Op. EBITDA3Q26 Op. EBITDA+40.0%+33.3%+16.4%−8.6%

Source: Company earnings releases; Penmark Research model.

How we hair-cut management guidance

We discount productivity promises by 50% at mid-cycle, not 0% or 100%. In 1Q26, Operating EBITDA of $873m beat the ~$750m guide (+16%); in 3Q26, initial ~$1,700m guidance was cut to ~$1,475m on feedstock spikes before landing at $1,553m (−9% vs initial). That record supports crediting 85% of FY27E cost cuts ($1.1bn vs $1.3bn guided) and 50% of productivity ($0.7bn) plus 100% of assumed European shutdown savings ($0.2bn).

Exhibit 42: Gross debt reaches our 2.5x leverage rule in FY27E, restarting buybacks to cut diluted shares to 696m
Gross debt / Op. EBITDA (FY24A–28E)FY28E: 2.36xFY24AFY28EDiluted shares (FY24A–28E)FY28E: 696.4mFY24AFY28E

Source: Company filings (FY24A–FY25A); Penmark Research model (FY26E–FY28E hatched). Our 2.5x gross leverage rule sits below Fitch’s 3.0x threshold.

Exhibit 43: Return on capital uses against Dow’s 7% WACC & balance-sheet actions
Capital use / action Scale ($bn) Return vs 7.3% WACC Assessment & per-share impact
Path2Zero cracker $7.5bn gross
($6.2bn net)
Accretive (+$2.7bn NPV): lifts group ROIC to 13.5% by FY35E. 1–2 year pause during FY25 preserved cash; ~45% built; $1.0bn run-rate EBITDA plus APIP grants of about C$1.8bn (US$1.3bn, paid post-start-up) add +$3.70/sh.
Maintenance & incremental capex $1.5bn–$2.0bn
per year
Above WACC (10.7% mid-cycle ROIC): alkoxylates add +$60m FY27E. Total capex held at $2.5bn in FY26E (below $2.7bn D&A) to protect investment-grade credit ratings.
Common dividend (post-50% cut) $1.0bn/yr
($1.40/sh)
4.6% cash yield: covered 2.9x by FY26E FCF ($3.0bn). Cutting from $2.80 to $1.40/sh in Jul 2025 stopped debt-funded payouts ($1.5bn paid vs −$1.4bn FCF in FY25A).
Infrastructure & litigation cash ~$4.2bn
inflows
Balance-sheet bridge: non-core monetisation at infrastructure yields. Macquarie 49% Diamond Infrastructure stake (~$3.0bn proceeds; NCI $3.4bn at market) + $1.2bn Nova judgment.
Share buybacks vs stock-based comp. (SBC) $0.2bn FY27E
$1.1bn FY28E
Value-accretive at $30.37: 24% discount to $39.78 base value. Paused in FY25–26E (shares rose 705m to 726m); restarts ($230m FY27E, $1,088m FY28E) under our 2.5x gross leverage rule.

Source: 2026 DEF 14A; 3Q26 release; Penmark Research model (7.30% capital asset pricing model [CAPM] WACC).

What management’s record means for value. Cutting the dividend by half and monetising Gulf Coast infrastructure showed management will put the balance sheet first. Karen Carter’s 30% Transformation bonus weight directly backs our $0.9bn (+$8.05/sh) assumed self-help credit.
PART 3 · THE THESIS · 9 EMPIRICAL STOCK DRIVERS

Dow trades on polyethylene spreads, cost cuts and dividend cover, not GAAP EPS

Four empirical tests across eight earnings prints, 105 weekly returns and 64 analyst questions isolate three confirmed stock drivers. Headline generally accepted accounting principles (GAAP) EPS rarely moves the shares on its own. Investors re-price Dow when resin spreads, cost self-help or balance-sheet cash coverage shift.

Exhibit 44: Confirmed stock drivers: test pass count, market reaction vs Penmark value & next dated number to watch
Confirmed driver Tests passed Market reaction vs model value Linked key debate Next number to watch
Integrated polyethylene spreads Four of four
(events, returns, ordinary least squares [OLS], Q&A 45%)
Stock jumped +15.9% (from $29.93) on the 3Q26 beat plus PE nominations, then fell −12.5% on 5.15% 10Y yields and weaker benzene; transient 1¢/lb is worth $0.21/sh vs structural 1pp margin worth $4.25/sh. Polyethylene margin floor Nov/Dec PE contract settlement (mid-Dec 2026): +5¢/lb nominated vs Penmark −4¢/lb FY27E reset.
Transform to Outperform cost self-help Three of four
(events, returns, Q&A 36%)
3Q25 (+13.0%) & 3Q26 (+4.7%) jumped on cost beats, yet $30.37 prices ~0% mid-cycle retention vs our +$8.05/sh ($867m) credit. Self-help durability 4Q26 results & FY27 bridge (late Jan 2027 est.): Penmark $1.1bn (85% of guide) vs $1.3bn guided.
Cash conversion & dividend/rate safety Four of four
(events, returns, 10Y US Treasury [UST] OLS, Q&A 28%)
2Q25 dividend cut sank stock −17.5%; 10Y UST hitting 5.15% plus weaker benzene cut stock −12.5%; +1pt WACC cuts target by −$10.91/sh to $26.93. Path2Zero optionality 4Q26 FCF & working capital (late Jan 2027 est.): >$500m 2H26 WC release; FY26E FCF $3.0bn.

Source: Earnings call transcripts; Yahoo Finance price history; Penmark Research model.

Exhibit 45: 2Q25 dividend cut (−18%) & 3Q25/26 beats led moves
−20%−10%0%+10%+20%4Q241Q252Q253Q254Q251Q262Q263Q26−6.1%+2.6%−17.5%+13.0%−2.2%−0.7%−1.1%+4.7%

Source: Yahoo Finance one-day closes on Dow’s last eight earnings releases (30 Jan 2025 to 22 Oct 2026).

Exhibit 46: DOW rose 39% in 12M, trailing S&P by 104pp over 3Y
DOWS&P 500−50%−25%0%+25%+50%+75%1M3M12M3Y5Y+2%−4%−3%−5%+39%+11%−41%+62%−48%+56%

Source: Yahoo Finance price return series to 18 Nov 2026.

Event-day reactions: cash and costs beat EPS

Three of the eight largest post-earnings moves exceeded ±5%, and each followed a cash, cost or resin-spread inflection. On 24 July 2025 (2Q25), halving the quarterly dividend from $0.70 to $0.35 drove a −17.5% one-day drop (−17.5pp excess vs S&P 500). Conversely, 3Q25 (+13.0%) and 3Q26 (+4.7%, +5.9pp excess) rallied on cost delivery, >$0.4bn working-capital release and +17% P&SP local pricing.

Return decomposition: earnings vs multiple

Over three and five years (−41% and −48%), collapsing EBITDA overwhelmed counter-cyclical multiple expansion. Operating EBITDA fell 41% in FY25A ($3.3bn vs $5.5bn), lifting EV/EBITDA to 13.9x at trough. Over the past 12 months (+39%), rebounding EBITDA toward $6.3bn compressed FY26E EV/EBITDA back to 7.2x as the stock rallied off its $20.93 intraday 52-week low.

PART 3 · THE THESIS · 9 FACTOR SENSITIVITY, CALL Q&A AND DROPPED CANDIDATES

Oil-to-gas spreads, 10Y yields and self-help Q&A confirm where the market misprices Dow

Exhibit 47: Weekly return variance share (105 wks, R² = 0.39)
Company-specificMaterials sector (XLB)Oil-to-gas ratio10Y Treasury yieldS&P 500 market61.5%16.4%8.5%7.8%5.8%

Source: Yahoo Finance weekly returns (Nov 2024–18 Nov 2026, n = 105); Penmark OLS.

Exhibit 48: Analyst Q&A share across 7 calls (n = 64 multi-topic turns)
PE pricing & spreadsCost savings & T2OCash, capex & dividendTariffs & macroMDI & housing45.3%35.9%28.1%28.1%7.8%

Source: Earnings call transcripts (1Q25–3Q26, 7 Q&A calls, n = 64 turns; shares sum to 145% as turns span multiple topics); Penmark analysis.

Integrated polyethylene spreads

Claim: Oil-to-gas feedstock spreads set Dow’s weekly tape (confirmed by all four tests; 45% of Q&A; 9% OLS variance share).

Market vs model: Shares surged +15.9% (from $29.93) on the 3Q26 beat plus Oct/Nov PE nominations, then fell −12.5% as 10Y yields hit 5.15% and benzene softened. In our model, a 1-year ±4¢/lb (±$0.8bn) swing moves PV by just ±$0.86/sh (±3%), whereas a lasting ±1pp mid-cycle margin shift is worth ±$4.25/sh (±14%).

Debate & watch: Links to Polyethylene margin floor. Watch mid-Dec 2026 contract settlement (+5¢/lb nominated vs our −4¢/lb FY27E reset; ±4%–6% move).

Transform to Outperform self-help

Claim: Cost and European shutdown delivery drives earnings-day re-ratings (confirmed by three of four tests; 36% of Q&A; confident management tone).

Market vs model: 3Q25 (+13.0%) and 3Q26 (+4.7%) rewarded cost beats, yet at $30.37 the market prices ~0% retained productivity ($31.74 implied value). Our model values $0.9bn of assumed mid-cycle self-help at +$8.05/sh (+27% vs spot), leaving an ~$8/sh valuation gap.

Debate & watch: Links to Self-help durability. Watch late-Jan 2027 4Q26 release for the FY27E bridge ($1.1bn Penmark vs Street ~$220m implied; ±5%–8% move).

Cash conversion & rate/dividend safety

Claim: Free cash flow cover of the $1.40 dividend and 10Y Treasury yields govern downside beta (confirmed by all four tests; 28% Q&A; 8% OLS variance share).

Market vs model: The 2Q25 dividend cut sank DOW −17.5%, and 10Y yields hitting 5.15% plus weaker benzene knocked −12.5% off the shares in Nov 2026. Our model confirms steep rate leverage: +1pt WACC cuts our target by −$10.91/sh (−29% to $26.93, Hold) and 1.60x beta cuts it to $24.31 (Sell).

Debate & watch: Links to Path2Zero optionality. Watch late-Jan 2027 4Q26 FCF (>$0.5bn 2H26 WC release; FY26E FCF $3.0bn vs Street ~$2.3bn; ±4%–7% move).

Exhibit 49: Three widely watched macro/GAAP narratives fail at least three of four stock-driver tests
Candidate tested Tests passed Evidence from our four tests & why dropped
MDI & housing cycle One of four (hedged call tone; 8% Q&A) Housing drives 40% of MDI demand, but II&I is only 15.4% of FY26E segment EBITDA ($986m of the three-segment sum) and housing turnover added negligible explanatory power beyond 10Y Treasury yields.
Tariff headlines & FX One of four (28% Q&A mentions) Frequently asked on 1H25–1H26 calls, yet local production (91 sites in 29 countries) blunted direct margin hits and trade-policy dates failed event-study significance.
Standalone quarterly GAAP EPS Zero of four Restructuring charges ($2.6bn FY25A GAAP loss vs −$0.93 operating EPS) decouple GAAP EPS from cash generation; 1Q26–2Q26 prints moved ≤1.1% despite GAAP noise.

Source: Earnings transcripts and company filings; Yahoo Finance; Penmark Research.

Methodological limits: Weekly OLS regression covers 105 weeks (Nov 2024–18 Nov 2026; 3-year 157-week sample yields R² = 0.34). Daily US Gulf Coast ethylene-to-ethane spreads are proxied using the WTI crude oil to Henry Hub natural gas price ratio. Q&A coding spans 64 multi-topic analyst turns across seven Q&A calls (1Q25–3Q26).

PART 3 · THE THESIS · 10 STRUCTURAL SELF-HELP AND EUROPEAN ASSET PRUNING

Keeping half of T2O productivity plus European closures adds about $0.9bn of mid-cycle EBITDA, or $8 a share

The claim (resting on Transform to Outperform cost self-help): Physical European plant shutdowns and headcount reductions lift Dow’s mid-cycle EBITDA margin by +1.9pp to 16.7%, adding +$8.05 per share that the market prices near zero.
Exhibit 50: We model $1.1bn FY27E self-help (85% of $1.3bn guide)
Penmark baseManagement target$0m$500m$1,000m$1,500mFY25AFY26EFY27EActualEstimates$400m$300m$700m$700m$1,105m$1,300m

Source: 3Q26 release; Penmark Research model.

Exhibit 51: Base value ($/sh) vs T2O kept & Path2Zero EBITDA
$33.6$36.0$38.3$40.7$43.0$34.3$36.7$39.0$41.4$43.7$35.1$37.4$39.8$42.1$44.5$35.8$38.2$40.5$42.9$45.2$36.6$38.9$41.3$43.6$46.0T2O productivity kept0%25%50%75%100%Alberta EBITDA$800m$900m$1,000m$1,100m$1,200m

Source: Penmark Research model.

What the market believes vs our evidence

Consensus models FY27E EBITDA falling to $5.5bn (−$0.7bn y/y) and prices zero retained self-help at $30.37. In commodities, investors rightly suspect cost cuts leak to customers. Yet three independent sources separate Dow’s programme from generic belt-tightening:

1. Audited restructuring charges & beat cadence: Dow booked $675m of T2O severance ($481m) and implementation ($194m) charges in 9M26A. Management beat FY25 cost savings by $100m ($400m vs $300m) and raised FY26 T2O delivery from $500m to $700m on the 3Q26 call.

Physical closures, incentives & per-share value

2. Permanent plant exits: Dow shut upstream siloxanes at Barry in 2Q26 and plans to close crackers at Böhlen and chlor-alkali/vinyls at Schkopau in Germany. Those exits remove negative-margin capacity worth $0.2bn a year by 2029 without higher resin prices.

3. Incentive alignment & valuation impact: Tying 30% of 2026 executive bonuses to T2O backs execution. Crediting 50% of $1.3bn productivity ($667m) plus 100% of closures ($200m) adds $867m of mid-cycle EBITDA, worth $5.9bn of EV or +$8.05 per share before remaining restructuring cash.

Exhibit 52: Self-help components, hair-cuts applied & dated signposts that confirm or break the pillar
Self-help stream Management target Penmark credit Value / sh Dated signpost (confirm vs disprove)
T2O productivity (~4,500 roles) ~$1,333m productivity (~2/3 of $2.0bn). $667m mid-cycle (50% kept); $1,105m (85% of guide) in FY27E. +$6.19/sh
($4,502m EV)
Late Jan 2027 (4Q26 print): Confirm if FY26 T2O ≥$700m & FY27E delivery ≥$1.0bn; broken if inflation erodes >50% ($35.09/sh at 0% kept).
T2O commercial growth uplift ~$667m growth (~1/3 of $2.0bn). $0m lasting credit (0% kept at mid-cycle). $0.00/sh
(upside option)
2Q27–3Q27 results: 75% productivity retention plus 100% FY27E delivery adds +$3.30/sh; full 100% retention adds +$4.70/sh ($44.48).
European asset shutdowns (Böhlen, Schkopau; Barry shut 2Q26) $200m annualised by 2029 (starts mid-2026). $200m mid-cycle (100% of assumed fixed-cost exit). +$1.86/sh
($1,350m EV)
Mid-2027 & end-2027 filings: Decommissioning milestones on schedule & remaining after-tax exit cash stays inside our $0.8bn deduction.

Source: 3Q26 release and call; Penmark Research model (+$6.19/sh T2O and +$1.86/sh closures = +$8.05/sh gross at 6.75x; net of the present value of the after-tax profit shortfall below mid-cycle, 4Q26E to FY30E, total credit is +$4.63/sh [$39.78 vs $35.15] and 0% T2O is $35.09/sh).

PART 3 · THE THESIS · 11 US ETHANE ADVANTAGE AND POLYETHYLENE CYCLE FLOOR

US Gulf Coast crackers (>90% rate) absorb a 4¢/lb FY27E PE fade while keeping EBITDA 16% above Street

The claim (resting on Integrated polyethylene spreads): Even assuming 2026’s conflict-assisted resin rally gives back 4¢/lb (−$0.8bn) in FY27E, North American ethane integration and 5%–6% global cracker closures anchor Dow’s through-cycle base at 14.8% before self-help.
Exhibit 53: P&SP EBITDA peaked at $1.6bn in 2Q26 and held $1.0bn in 3Q26
$0m$500m$1,000m$1,500m$2,000m1Q252Q253Q254Q251Q262Q263Q26$702m$440m$548m$576m$590m$1,639m$954m

Source: Company quarterly releases and 3Q26 Form 8-K.

What the market believes vs three evidence lines

Consensus models a $0.7bn EBITDA drop in FY27E ($5.5bn vs $6.3bn) because brokers assume Middle East peace erases 2026’s PE bounce without offset. Our base case already bakes in a −4¢/lb (−$0.8bn) PE fade plus −$0.3bn MDI normalisation and still lands at $6.4bn (+$0.9bn above Street):

1. Reported P&SP operating leverage: When export logistics tightened in 2Q26, P&SP EBITDA jumped from $440m (2Q25) to $1,639m before easing to $954m in 3Q26. That remained 74% above 3Q25’s $548m, with local prices up 17% y/y, showing US Gulf Coast cost-curve torque.

2. US ethane vs global naphtha: Management reports US Gulf Coast crackers run above 90% with ethane near its 5-year average, whereas global ethylene runs in the low 80s.

3. Capacity closures & 7-yr cycle base: Announced closures reach 5%–6% of global ethylene (~8% speculated) toward management’s ~10% mid-cycle threshold, supporting Dow’s 14.8% FY19A–25A average margin over FY23–25’s 11.0% trough.

Exhibit 54: Polyethylene spread & cycle assumptions: impact on FY27E EBITDA, value per share & dated signposts
Spread / cycle case Operating assumption EBITDA impact Value / share Dated signpost (confirm vs disprove)
Penmark Base Case (55% weight) FY27E PE resets −4¢/lb; existing margins reach 16.7% by FY30E (14.8% hist. + 1.9pp T2O). FY27E $6,434m;
Norm. $7,639m
$39.78/sh
(base value)
Mid-Dec 2026 & 1Q27 print: USGC cracker rates stay above 90% and FY27E PE contract give-back stays ≤4¢/lb.
Oct/Nov PE hikes stick (Catalyst upside) Oct +7¢/lb and Nov +5¢/lb nominations settle and hold through 1H27 (+4¢/lb vs base). FY27E +$800m
(to $7,234m)
+$0.86/sh
(1-yr cash PV)
Dec 2026 CDI/Argus settlements: Net contract increase ≥+5¢/lb holds into 1Q27 without Asian import arbitrage.
Further EU/Asia closures (Bull structural) Speculated 8%–10% global ethylene closures formalised, lifting mid-cycle margin +50bp. Norm. +$229m
(to $7,868m)
+$2.13/sh
(Bull $50.92)
1H27–Oct 2027 peer updates: Additional European/Northeast Asian cracker shutdowns lift global rates above 85%.
Trough margin risk vs full Bear case New China/ME builds cap historical margin at 11.0% (credit held) vs full Bear (55% FY27E self-help, none kept at mid-cycle, −6¢/lb more PE fade). Risk: −$1,729m norm.
Full Bear: $4,552m FY27E
−$16.04/sh risk
($16.20 full Bear)
3Q27 operating-rate check: Global ethylene stays ≤80%, Middle East JVs restart into oversupply and PE drops ≥6¢/lb.

Source: Dow 3Q26 call; Penmark Research model. Trough margin risk alone cuts normalised EBITDA by $1,729m (−$16.04/sh); the full Bear scenario combines lost self-help, −6¢/lb PE and Sadara to reach $4,552m FY27E EBITDA and $16.20/sh.

Why transient vs structural matters. One year of ±4¢/lb PE pricing moves equity value by less than $1/sh, whereas shifting Dow’s mid-cycle margin floor between 11.0% (trough) and 16.7% (base) swings value by more than $23/sh.
PART 3 · THE THESIS · 12 PATH2ZERO ALBERTA VALUE AND CASH CONVERSION

Path2Zero adds $2.7bn, nearly $4 a share, and FCF covers the dividend about two to three times

The claim (resting on Cash conversion & dividend safety): With ~45% of Path2Zero already built and ~$1.3bn of Canadian incentives assumed post-start-up, Path2Zero adds +$3.70 per share net of remaining capex while 72%–87% cash conversion funds the dividend.
Exhibit 55: Path2Zero net present value build ($2.7bn = +$3.70/sh)
$0m$1,000m$2,000m$3,000m$4,000m$5,000mRun-rateEV PVRemainingcapex PVAPIPincentives PVFY30–31ramp PVAlberta netNPV$4,662m−$3,581m+$898m+$714m$2,693m

Source: Penmark Research model (7.3% WACC, 6.75x run-rate multiple).

Exhibit 56: Self-help & Path2Zero execution schedule (2024–2032)
20242026202820302032Self-helpT2O role cuts & costprogrammeEU cracker & siloxaneclosuresAlbertaPath2Zero peak build(~45% done)Phase 1 start-up (40%ramp)Phase 2 & APIP cashincentives20 Nov 2026$2.0bn target+$200m run-rate$7.5bn total$1.0bn EBITDA

Source: 3Q26 and 4Q25 calls; Penmark Research model.

What the market believes vs sunk-capex reality

Near-term consensus multiples penalise Dow for $4.1bn of remaining FY27E–FY30E Path2Zero construction capex while crediting zero FY30E–FY32E EBITDA. Three facts refute treating Path2Zero as a zero-NPV cash sink:

1. About 45% of capital is already sunk: Of the $7.5bn gross project budget, roughly $3.4bn has been spent through late 2026. Remaining construction capex ($1.15bn in FY27E, $1.2bn each in FY28E and FY29E, and $0.58bn in FY30E) has a present value of −$3.6bn.

2. APIP grants reduce net cost to $6.2bn: Alberta Petrochemicals Incentive Program (APIP) grants of about C$1.8bn (US$1.3bn) cut net project cost from $7.5bn to $6.2bn. We assume two $650m payments after start-up in FY31E–FY32E (+$0.9bn PV); federal credits are not modelled.

Cash conversion, Sadara & dated signposts

3. Cash conversion funds both capex and the $1.0bn dividend: Continuing CFO surged from $1.1bn in FY25A to $4.3bn in 9M26A (91% conversion, 84% trailing twelve months), leaving $2.4bn of 9M26A FCF after $1.8bn of capex. From FY26E to FY29E, FCF ($3.0bn, $2.0bn, $2.4bn, $2.7bn) covers common dividends 2.9x, 1.9x, 2.4x and 2.5x.

Value & Sadara link: Capitalising $1.0bn of FY32E Path2Zero EBITDA at 6.75x ($4.7bn PV) plus +$0.7bn FY30E–31E ramp PV yields +$2.7bn (+$3.70/sh); ±$200m on run-rate EBITDA moves value by ±$1.48/sh. Exiting Sadara below our $1.3bn deduction ($758m negative investment + $500m guarantee) adds +$0.35/sh upside vs −$0.40/sh if called.

Confirming signposts (late Jan & mid-2027): 4Q26 working-capital release tops $0.5bn for 2H26; FY27E group capex guidance stays ≤$2.8bn with Phase 1 start-up affirmed for end-2029; Sadara strategic review caps Dow cash exposure ≤$1.0bn.
Disproving signposts (thesis break): Remaining Path2Zero capex overruns >20% (~$8.3bn gross total) or slips past 2031; CFO/EBITDA conversion drops below 60% in FY27E, pushing FCF below the $1.0bn dividend; or Aramco/lenders call the full Sadara guarantee.
Summary across all three thesis pillars. Starting from the $30.37 share price, self-help (+$8.05), Path2Zero (+$3.70), Sadara (+$0.40) and margin (+$0.04), less −$2.77 of recovery-path drag, bridge directly to our $39.78 base value.
PART 4 · THE NUMBERS · 13 TRACK RECORD AND QUALITY OF REPORTED NUMBERS

Margins ranged from 8% to 23% over seven years; restructuring charges opened a wide GAAP gap

Exhibit 57: Seven-year reported & operating track record (FY19A–FY25A and 9M26A, US$m except per share)
Line item FY19AFY20AFY21AFY22AFY23AFY24AFY25A9M26A
Net sales42,95138,54254,96856,90244,62242,96439,96833,153
Net sales growth, y/yn.a.−10.3%+42.6%+3.5%−21.6%−3.7%−7.0%+8.7%
Operating EBITDA7,2905,58912,3759,3485,3895,4823,2564,738
Operating EBITDA margin17.0%14.5%22.5%16.4%12.1%12.8%8.1%14.3%
Operating EBIT4,3522,7159,5336,5902,7782,5884222,689
GAAP net income to Dow Inc.−1,3591,2256,3114,5825891,116−2,623646
GAAP diluted EPS ($/sh)−1.841.648.386.280.821.57−3.70n.a.
Operating diluted EPS ($/sh)n.a.n.a.n.a.n.a.2.241.71−0.932.04
Capital expendituresn.a.1,2521,5011,8232,3562,9402,4791,841
Operating ROIC after tax12.1%8.5%24.4%15.7%6.9%6.3%1.0%n.a.

Source: FY19–FY25 Form 10-K filings and 3Q26 release; Penmark Research model. n.a. = not available in model series. 9M26A operating EPS of $2.04 uses the nine-month diluted share count; reported quarters sum to $2.02.

Exhibit 58: CFO rebounds from $1.1bn (33%) to $5.5bn (87%)
Operating cash flowCash conversion (right)$0m$2,000m$4,000m$6,000m20%40%60%80%100%FY25AFY26EFY27EFY28EFY29EActualEstimates

Source: Company filings (FY25A); Penmark Research model (FY26E–29E).

Exhibit 59: Accounting quality & off-balance-sheet audit (Sep-26)
ItemReported scaleQuality check & model treatment
GAAP “significant items”−$1,961m FY25A;
−$829m 9M26A
GAAP restructuring & EU asset write-downs excluded from operating earnings widened the GAAP gap ($646m vs $1,475m in 9M26A); we deduct $0.8bn remaining after-tax restructuring cash in our EV bridge.
Sadara JV exposure$758m neg. inv.
+$500m guar.
Carried in noncurrent obligations and fair-value guarantees (Notes 9 & 19); we deduct the full $1,258m in our equity bridge.
Pension & OPEB deficit$4,318m pre-tax
($3,239m net)
Down from $4,694m at Dec-25; deducted after tax in full ($3.2bn) rather than ignored in EBITDA multiples.
Environmental & asbestos$991m + $564m
($1,166m net)
10-Q Note 12 flags environmental costs up to ~2.5x accrued as reasonably possible; after-tax accruals ($1.2bn) deducted in EV bridge.
Deferred rev. & leases$199m def. rev.;
$1,369m leases
Minimal prepayments ($199m vs $221m Dec-25); operating leases included on GAAP balance sheet.

Source: 3Q26 Form 10-Q Notes 9, 12 & 19; Penmark Research model.

Price/volume split & earnings basis. Revenue swings since FY21A ($55.0bn to $40.0bn in FY25A, then +13% y/y in 3Q26 on +14% local price and −1% volume) are overwhelmingly price-driven rather than M&A-driven. Throughout this report we use company-defined Operating EBITDA ($3.3bn in FY25A = $422m Op. EBIT + $2,834m D&A) and full-capex free cash flow (−$1.4bn in FY25A = $1,062m continuing CFO less $2,479m capex).
PART 4 · THE NUMBERS · 14 FORECASTS: REVENUE EQUATION AND SEGMENT PATH

Operating EBITDA climbs from $6.3bn in FY26E to $8.0bn in FY30E as self-help and Path2Zero arrive

Exhibit 60: FY27E forecast driver tree: $1.1bn of self-help outweighs −4¢/lb PE reset to lift EBITDA to $6.4bn
PE margin −4¢/lb−$800m EBITDAVolume +2% & 50% T2O+$644m EBITDAP&SP FY27E$21,939m | EBITDA $4,107mMDI normalise−$300m EBITDAAlkoxylates & 25% T2O+$336m EBITDAII&I FY27E$11,462m | EBITDA $1,022mSilicones vol +3%Net $0m vs siloxanesPM&C 25% T2O share+$276m EBITDAPM&C & Corp FY27E$9,713m | EBITDA $1,304mFY27E Net sales$43,115m (−2.1% y/y)FY28E–30E Existing+2.0%/yr organic sales;margin steps 15.5% to16.7% by FY30EPath2Zero RampFY30E: $960m / $400m;FY31E: $2,040m / $850m;FY32E: $2,400m / $1,000mLong-Cycle FY35ESales $52,916m;Op. EBITDA $9,417m;Op. EPS $7.77 | ROIC 13.5%

Source: Penmark Research model (FY27E operating bridge).

Exhibit 61: Consolidated Operating EBITDA climbs from $3.3bn in FY25A to $9.4bn by FY35E ($7.77 Op. EPS)
Operating forecast FY25A9M26A4Q26EFY26EFY27EFY28EFY30EFY35E
P&SP net sales19,97017,0825,80022,88221,93922,37823,28225,705
II&I net sales11,1638,8502,85011,70011,46211,69212,16413,430
PM&C & Corporate net sales8,8357,2212,2309,4519,7139,90710,30811,381
Alberta Path2Zero net sales0000009602,400
Consolidated net sales39,96833,15310,88044,03343,11543,97746,71452,916
Net sales growth, y/y−7.0%+8.7%+15.0%+10.2%−2.1%+2.0%+4.1%+1.9%
Existing-assets Operating EBITDA3,2564,7381,5506,2886,4346,8177,6248,417
Alberta Path2Zero EBITDA0000004001,000
Consolidated Operating EBITDA3,2564,7381,5506,2886,4346,8178,0249,417
Operating EBITDA margin8.1%14.3%14.2%14.3%14.9%15.5%17.2%17.8%
Depreciation & amortisation2,8342,0496702,7192,7262,7172,7303,055
Operating EBIT4222,6898803,5693,7074,1005,2936,362
Operating net income to Dow−6621,4754921,9672,0722,3993,2674,013
Operating diluted EPS ($/sh)−0.932.040.682.712.873.445.217.77

Source: Company filings (FY25A, 9M26A); Penmark Research model (ten-year long-cycle forecast to FY35E). 9M26A operating EPS of $2.04 uses the nine-month diluted share count; reported quarters sum to $2.02.

Revenue path: FY27E reset, then +2% + Path2Zero

Because chemical cycles span seven to ten years, we model ten explicit forecast years through FY35E. After FY26E’s +10% price-led rebound ($44.0bn, including $10.9bn in 4Q26E), FY27E sales dip −2% to $43.1bn as −4¢/lb PE and MDI resets outweigh +2% P&SP and +3% downstream silicones volume growth. Existing assets then grow +2%/yr while Path2Zero adds $1.0bn in FY30E, $2.0bn in FY31E and $2.4bn at full run-rate in FY32E.

Fixed/variable cost path & operating leverage

Existing-asset EBITDA margins step linearly from 14.9% in FY27E to 16.7% at FY30E mid-cycle. Variable NGL/naphtha spreads normalise gradually while fixed-cost removal ($1.1bn in FY27E, 85% of guide, plus European shutdowns completing by 2029) lifts margins; D&A holds flat near $2.7bn through FY30E because capex stays at or below D&A. Adding high-margin Path2Zero ethane tons (42% EBITDA margin) lifts consolidated margin to 17.2% in FY30E and 17.8% in FY35E.

PART 4 · THE NUMBERS · 14 PENMARK VS CONSENSUS, CASH PATH AND DRIVER SENSITIVITY

In line with the Street for FY26E, then 16% above on FY27E EBITDA and 56% above on EPS

Exhibit 62: Line-by-line Penmark vs Street consensus & management guidance with reason for each gap
Period & metric Penmark Consensus / Guide Gap Analytical reason for gap
4Q26E Op. EBITDA ($m)1,550~1,500 guide+3.3%Partial Oct PE +7¢/lb carry-over offsets normal 4Q packaging seasonality ($6.2bn FY guide).
FY26E Net sales ($m)44,03343,886 Street+0.3%9M26A $33.2bn actuals leave only $10.9bn in 4Q26E; top line is essentially locked.
FY26E Op. EBITDA ($m)6,2886,296 Street−0.1%In line with Street mean ($6.3bn) and +0.8% above management’s implied $6.2bn guide.
FY26E Op. EPS ($/sh)2.712.58 Street+5.1%Street’s implied 4Q26E EPS ($0.56: FY $2.58 less 9M $2.02) looks low for ~$1.55bn of EBITDA; brokers’ below-the-line assumptions are not visible.
FY27E Net sales ($m)43,11543,027 Street+0.2%Both Penmark (−2.1%) and Street (−2.0%) model 2026 resin pricing easing in FY27E.
FY27E Op. EBITDA ($m)6,4345,548 Street+16.0%Core gap (+$886m): Street models −$748m fade with minimal T2O offset; we pair +$1,105m T2O (85% of guide) against −$800m PE & −$300m MDI.
FY27E Op. EPS ($/sh)2.871.84 Street+56.0%Fixed D&A ($2.7bn) and net interest ($0.7bn) magnify the +$886m EBITDA gap at the bottom line.
FY28E Op. EBITDA ($m)6,8175,731 Street+19.0%Continued EU shutdown savings and +60bp margin step toward 16.7% mid-cycle (+$1.1bn vs Street).

Source: S&P Global consensus; company guidance; Penmark Research model.

Exhibit 63: Cash flow, Path2Zero capex split, our 2.5x gross leverage rule & buyback path (US$m)
Cash & balance-sheet bridge FY25AFY26EFY27EFY28EFY29EFY30E
Cash from operations (CFO)1,0625,4634,6185,1485,4705,972
Capital expenditures, total−2,479−2,501−2,650−2,750−2,800−2,575
of which Path2Zeron.a.n.a.−1,150−1,200−1,200−575
Free cash flow (FCF)−1,4172,9621,9682,3982,6703,397
Common & NCI dividends−1,490−1,315−1,316−1,310−1,379−1,506
Debt repaid / (drawn)n.a.7481,255000
Share buybacks (at rolled base value)00−230−1,088−1,290−1,891
Ending net debt ($m) / Net debt/EBITDA14,345 (4.41x)13,206 (2.10x)12,784 (1.99x)12,784 (1.88x)12,784 (1.77x)12,784 (1.59x)

Source: FY25 Form 10-K; Penmark Research model (minimum cash floor $3.3bn from FY27E; gross debt $16.1bn under our 2.5x gross leverage rule, below Fitch’s 3.0x trigger; n.a. = not available separately).

Exhibit 64: FY27E sensitivity to confirmed stock drivers
Driver shockEBITDAOp. EPSFCF
Base case FY27E$6,434m$2.87$1,968m
PE margin ±1¢/lb±$200m±$0.22±$156m
PE margin ±4¢/lb (no fade / 2x fade)±$800m±$0.86±$624m
T2O FY27E at 100% vs 55% (vs 85%)+$195m / −$390m+$0.21 / −$0.42+$152m / −$304m
MDI & housing ±$200m±$200m±$0.22±$156m

Source: Penmark Research model (22% operating tax rate).

Balance-sheet rules in our model

Deleveraging comes before buybacks. Excess cash repays $0.7bn of debt in FY26E and $1.3bn in FY27E until gross debt reaches $16.1bn under our 2.5x gross leverage rule with $3.3bn of minimum cash. Only above that threshold does surplus cash retire shares, priced conservatively at the higher of share price and rolled base value ($40.95/sh in FY27E rising to $47.10/sh in FY30E) so buybacks never artificially inflate per-share value. Spot net debt at 30 Sep 2026 is $13.4bn ($17.5bn debt less $4.1bn cash).

PART 4 · THE NUMBERS · 15 VALUATION: PRIMARY MID-CYCLE EV/EBITDA & PEER ANCHOR

At 6.75x mid-cycle EBITDA plus Path2Zero, less $25bn of claims, base value is about $40 a share

Commodity chemical margins mean-revert, so we value Dow on mid-cycle EV / Operating EBITDA (6.75x) rather than trough or spike earnings. We reject standalone P/E (EPS swung from −$3.70 to $2.71E), sum-of-the-parts (shared ethylene crackers) and FY27E multiples (below mid-cycle operating rates).

Exhibit 65: Enterprise value of $54.3bn less $25.3bn of claims yields $28.9bn equity ($40/sh)
$0m$20,000m$40,000m$60,000mExisting assetsEVAlberta NPVNet debtNCI at marketPension &SadaraLegacy &restruct.Recovery-pathPVEquity value$51,563m+$2,693m−$13,397m−$3,439m−$4,497m−$1,966m−$2,018m$28,939m

Source: Penmark Research model at 18 Nov 2026 (727.4m diluted shares).

Exhibit 66: Primary valuation & equity bridge (US$m)
Valuation build (18 Nov 2026)ValuePer sh
Trend revenue (FY19A–25A avg)45,845$63.03
Historical mid-cycle margin (14.8%)6,772$9.31
Assumed self-help credit (50% T2O + EU)867$1.19
Normalised Op. EBITDA (16.7%)7,639$10.50
EV, existing assets at 6.75x51,563$70.89
Path2Zero project NPV2,693$3.70
Total enterprise value54,255$74.59
Less: Net debt ($17,539m − $4,142m)−13,397−$18.42
Less: NCI at market ($2,943m InfraCo+book)−3,439−$4.73
Less: Pension/OPEB ($3,239m) & Sadara ($1,258m)−4,497−$6.18
Less: Env./asbestos ($1,166m) & restruct. ($800m)−1,966−$2.70
Less: Recovery-path shortfall PV (to FY30E)−2,018−$2.77
Primary base equity value (727.4m sh)28,939$39.78
Memo: Value at 14.8% hist. margin (no credit)25,570$35.15

Source: Penmark Research model.

Exhibit 67: Chemical peer snapshot & 6.75x anchor
CompanyEV ($m)EV/EBITDAEV/SalesOp. mgnND/EB
LyondellBasell (LYB)25,5816.08x0.80x12.6%1.67x
Westlake (WLK)11,07115.36x0.97x1.4%4.29x
Eastman (EMN)11,925n.a.1.32xn.a.n.a.
Celanese (CE)15,0759.24x1.53x7.7%6.24x
Huntsman (HUN)3,13910.43x0.51x2.3%5.59x
Peer median (30 Sep 26)11,9259.84x0.97x5.0%4.94x
Dow at $30.37 (LTM)45,3898.28x1.07x8.1%2.45x
LYB 13y / Dow FY19–25n.a.6.74x / 6.86xn.a.14.8%n.a.

Source: Peer 3Q26 filings; GuruFocus; Penmark Research model. Dow LTM EV uses $45,389m full-bridge EV; peers and cycle medians use simple EV.

Multiples at $30.37 actual price vs $37.84 target. At $30.37 (diluted market cap $22,091m), spot full-bridge EV is $45,389m: 7.2x FY26E, 7.1x FY27E and 10.6x FY27E P/E. On a like-for-like basis including the $2.0bn recovery-path drag (ex-Path2Zero), the share price implies 5.85x normalised Op. EBITDA versus our 6.75x target multiple. At our $37.84 target ($50.8bn EV), Dow trades at 7.9x FY27E EV/EBITDA and 13.2x FY27E P/E.
PART 4 · THE NUMBERS · 15 SCENARIOS, RATING ROBUSTNESS AND MULTIPLE SENSITIVITY

Weighted value of $36 rolls to our $38 target (+29%), but two discount-rate tests flip the call

Exhibit 68: 75% of scenario weight sits above $30 ($36 weighted)
$0$20$40$60$16.20$39.78$50.92Bear25%Base55%Bull20%Weighted $36.11Price $30.37

Source: Penmark Research model (probability weights reflect analyst judgement).

Exhibit 69: High beta ($26 base; $24 target) & +1pt WACC ($29) flip call
Base at WACC ±1ptBase across beta rangeTarget multiple ±1.0xMid-cycle margin ±2ppT2O productivity retainedAlberta run-rate EBITDABase $39.78+1pt $28.54−1pt $56.251.60x $25.610.78x $48.145.75x $29.287.75x $50.2912.8% $31.2816.8% $48.290% $35.09100% $44.48$0.8bn $38.31$1.2bn $41.26

Source: Penmark Research model (bars show base value vs $39.78; rolled targets flip at $26.93 Hold and $24.31 Sell).

Exhibit 70: Bull, base & bear scenario assumptions, valuations and 12-month target roll-forward
Scenario & driver link (full model re-run) Bear (25%) Base (55%) Bull (20%) Prob.-wtd
FY27E PE margin vs FY26E / Self-help realisation−10¢/lb / 55%−4¢/lb / 85%0¢/lb / 100%n.a.
T2O productivity retained / Through-cycle margin0% / 11.0% (FY23–25)50% / 14.8% (FY19–25)100% / 14.8% + growthn.a.
Path2Zero run-rate EBITDA / Sadara deduction$700m / $1,550m$1,000m / $1,258m$1,100m / $1,000mn.a.
FY27E Op. EBITDA ($m) / Operating EPS ($/sh)$4,552m / $0.83$6,434m / $2.87$7,674m / $4.43n.a.
Normalised existing-asset Op. EBITDA ($m)$5,240m$7,639m$8,639m$7,239m
Primary value per share at price date (18 Nov 2026)$16.20 (−46.7%)$39.78 (+31.0%)$50.92 (+67.7%)$36.11 (+18.9%)
Rolled 12-month price target (at Ke 9.38% − yield 4.61%)$16.97 (−44.1%)$41.68 (+37.3%)$53.35 (+75.7%)$37.84 (+24.6%)
12-month total return incl. $1.40 dividend / Implied rating−39.5% (Sell)+41.9% (Buy)+80.3% (Buy)+29.2% (Buy)
Cross-check full-cycle DCF value per share$13.73$54.73$75.50$48.64

Source: Penmark Research model.

Exhibit 71: Primary value spans $22 to $60 across multiple & margin
$22.0$25.7$29.3$32.9$36.5$26.7$30.6$34.5$38.5$42.4$31.3$35.5$39.8$44.0$48.3$35.9$40.5$45.0$49.6$54.2$40.5$45.4$50.3$55.2$60.1Historical margin12.8%13.8%14.8%15.8%16.8%EV / EBITDA5.75x6.25x6.75x7.25x7.75x

Source: Penmark Research model (includes +1.9pp assumed self-help credit).

Reconciliation to Page 1 target & Low conviction

Weighting Bear ($16.20 × 25%), Base ($39.78 × 55%) and Bull ($50.92 × 20%) gives $36.11/sh today. Rolling $36.11 forward 12 months at cost of equity (9.4%) less dividend yield (4.6%) yields our $37.84 Page 1 target (+24.6% price upside, +29.2% rated total return).

Why conviction is Low: Lifting WACC by +1pt cuts our target to $26.93 (−6.7% total return, Hold), while global-chemical high-end levered beta (1.60x) cuts it to $24.31 (−15.3% total return, Sell). Removing the self-help credit alone ($33.08 target, +13.5% total return) keeps Buy.
PART 4 · THE NUMBERS · 15 FULL-CYCLE DCF CROSS-CHECK, GAP RECONCILIATION & REVERSE DCF

The DCF gives about $55 a share because it uses a lower discount rate than our 6.75x multiple implies

Definitions in plain English: Weighted average cost of capital (WACC, 7.3%) is the blended annual return debt and equity investors require to fund Dow’s assets. Terminal growth (2.0%) is the steady annual cash-flow growth assumed after our ten-year forecast ends in FY35E. A reverse discounted cash flow (reverse DCF) solves backwards from today’s $30.37 share price to find what discount rate or margin the market is implicitly pricing in.

Exhibit 72: DCF stays above $40 across 6%–8% WACC
$68.7$71.4$74.6$78.7$83.8$59.7$61.5$63.6$66.2$69.4$52.2$53.4$54.7$56.4$58.3$45.7$46.5$47.4$48.4$49.5$40.2$40.7$41.2$41.7$42.4Terminal growth1.0%1.5%2.0%2.5%3.0%WACC6.3%6.8%7.3%7.8%8.3%

Source: Penmark Research model.

Exhibit 73: Reconciliation of +38% DCF gap & reverse-DCF solves
Reconciliation & reverse-DCF solveValuevs Primary
Primary EV (after $2,018m recovery path)$52,237mn.a.
Full-cycle DCF EV (7.30% CAPM WACC)$61,837m+18.4%
DCF equity value /sh (rolled 1.0121x)$54.73/sh+37.6%
DCF with terminal at 6.75x FY35E EBITDA$47.01/sh+18.2%
DCF at zero terminal growth (g = 0%)$50.18/sh+26.1%
DCF at return on new invested capital (RONIC) = WACC (7.3%)$51.16/sh+28.6%
DCF at 8.19% rate embedded in 6.75x$42.46/sh+6.7%
Reverse DCF: Price-implied ERP / WACC7.89% / 9.44%=$30.37
Reverse multiple: Price-implied EV/norm. EB5.85x=$30.37
Reverse margin: Price-implied mid-cycle mgn14.45%=$30.37

Source: Penmark Research model.

Exhibit 74: Explicit ten-year unlevered free cash flow reaches $4.2bn in FY32E as incentives land (US$m)
DCF cash-flow build 4Q26EFY27EFY28EFY29EFY30EFY31EFY32EFY33EFY34EFY35E
Operating EBIT8803,7074,1004,4935,2935,9146,1766,2866,3236,362
Tax on EBIT (22.0%)−194−816−902−988−1,165−1,301−1,359−1,383−1,391−1,400
Depreciation & amortisation6702,7262,7172,7212,7302,7122,7562,8042,9293,055
Capital expenditures−660−2,650−2,750−2,800−2,575−3,737−3,826−3,894−4,025−4,158
APIP grants, WC & restruct. cash−56−480−268−232−325301424−167−170−173
Unlevered free cash flow (UFCF)6402,4882,8973,1943,9593,8894,1713,6473,6663,686
Present value at 7.30% WACC6352,3602,5612,6313,0392,7822,7812,2662,1231,989

Source: Penmark Research model (PV of explicit UFCF = $23.2bn; PV of terminal value = $38.7bn, 63% of $61.8bn DCF EV; claims = $22.5bn).

Why the +38% DCF gap exists, and why we anchor on the multiple: First, $22.5bn–$25.3bn of non-equity claims (~47% of EV) doubles an 18% EV gap into +38% at equity. Second, our 7.3% CAPM WACC (5.15% 10y UST, 4.14% equity risk premium [ERP], 1.02x levered beta, 4.7% after-tax debt) implies a 7.9x terminal EV/EBITDA at 9.0% return on new invested capital (RONIC) and 22% reinvestment, whereas 6.75x embeds an 8.2% discount rate. Discounted at 8.2%, DCF is $42.46/sh (+7% vs primary). No terminal growth down to −15% brings DCF to $30.37 at 7.3% WACC: the share price is pricing a 9.4% WACC (7.9% ERP), not zero growth.
PART 4 · THE NUMBERS · 16 CATALYSTS AND THESIS MONITORING FRAMEWORK

Fourth-quarter results and the FY27 self-help bridge in late January are the first big test

Exhibit 75: T2O retention (+$3.30) & closures (+$2.13) lead ~$6.70 upside
T2O productivity holds(45% prob.)Further EU/Asia closures(40% prob.)Oct/Nov PE hikes hold(35% prob.)Sadara exit below book(35% prob.)Middle East JV restarts(60% prob.)+$3.30+$2.13+$0.86+$0.35+$0.05

Source: Penmark Research model (unweighted $/sh; upside catalysts sum to ~$6.70/sh).

Next numbers to watch by confirmed stock driver

Integrated PE spreads: Nov/Dec 2026 CDI US contract settlements (+7¢/lb Oct and +5¢/lb Nov nominated; we take +1¢/lb in 4Q26E vs ~0¢ in guide; full settlement adds +$0.8bn FY27E EBITDA or +$0.86/sh).
Transform to Outperform self-help: Late Jan 2027 (est.) 4Q26 call FY27 bridge (Penmark $1.1bn, 85% of $1.3bn guide, vs ~$220m implied in Street $5.5bn EBITDA; 100% FY27E delivery adds +$195m EBITDA, while 75% mid-cycle retention adds +$3.30/sh).
Cash conversion & rate safety: 4Q26 CFO ($1.2bnE, $0.5bn 2H26 WC release) and Mar 2027 completion of ~$1.4bn debt retirement.

Exhibit 76: Dated 12–18 month catalyst calendar: Penmark expectation vs Street consensus
Timing Event & driver Penmark expectation Street / market view Stock & rating impact
Nov–Dec 2026Oct (+7¢/lb) & Nov (+5¢/lb) US PE contract settlements~1¢/lb sticks in 4Q26E; −4¢/lb fade in FY27EAssumes hikes fail and FY27E resets −8.4¢/lb+$0.86/sh if hikes stick across FY27E (35% prob.)
Late Jan 2027 (est.)4Q26 results & formal FY27 T2O self-help bridge4Q26E EBITDA $1,550m ($0.68 EPS); $1,105m (85% of guide)~$1,500m guide ($0.56 Street EPS); ~$5.5bn FY27E EBITDAPrimary re-rating event as FY27E Street revises up
Mar 2027~$1.4bn debt retirement milestone & 1Q27 PE checkGross debt steps toward $16.1bn (our 2.5x gross leverage rule)Sceptical on FCF cover of $1.40/sh dividendNarrows equity credit risk premium
1H 2027Sadara JV strategic review & Aramco talksSettled near $1,258m recorded obligationFears full guarantee call ($1,550m bear case)+$0.35/sh if settled ~$258m below book (35% prob.)
Mid-2027EU cracker closures & peer shutdowns (Barry shut 2Q26)Böhlen/Schkopau progress; global closures >6%Treats FY23–25 overbuild as permanent+$2.13/sh if extra closures add +0.5pp margin (40%)
Late 2027–1H28Path2Zero ~65%+ build & potential partner dealOn budget ($7.5bn gross; $1.0bn run-rate EBITDA)Zero NPV credit until 2029–30 start-upCrystallises $2.7bn ($3.70/sh) project NPV

Source: 3Q26 release and earnings call; Penmark Research model (4Q26 date estimated from prior late-Jan releases).

Exhibit 77: Thesis monitoring framework: what confirms or breaks our Buy call
IndicatorThesis confirmed ifThesis broken if (triggers downgrade review)
Integrated USGC PE marginFY27E give-back stays within −4¢/lb of FY26E; USGC crackers run >90%Middle East/China surge resets PE ≥8–10¢/lb lower; P&SP EBITDA <$3.2bn
T2O productivity retentionCost savings hit ≥$275m/qtr in FY27 (≥85% of $1.3bn target)Wage inflation & discounting erode >45% of savings; FY27E EBITDA <$5.2bn
Cash conversion & dividendCFO / Op. EBITDA stays 70%–80% and FY27E FCF ≥$1.8bn (>$1.3bn div.)Cash conversion drops <60% or working capital absorbs >$500m, forcing borrowing
Discount rate & chemical beta10Y UST stays ≤5.15% and levered beta near 1.02x (WACC ~7.3%)WACC +1pt (8.3%) cuts target to $26.93 (Hold); 1.60x beta cuts to $24.31 (Sell)

Source: Penmark Research model.

What would change our view: Because our conviction is Low, we would downgrade to Hold if 10-year Treasury yields or credit spreads push Dow’s WACC up +100bp to 8.3%, or if 1H27 results show T2O cost savings leaking into lower customer prices (pushing FY27E EBITDA toward Street’s $5.5bn). Conversely, we would raise our target toward $41–$45/sh if FY27E EBITDA exceeds $6.8bn with full productivity retention.
PART 4 · THE NUMBERS · 17 DOWNSIDE RISKS TO OUR BUY RATING AND $38 TARGET

A permanent China overbuild (−$16) and lost self-help (−$7) drive our $16 bear case

Exhibit 78: Permanent trough (−$16) leads downside risks
FY23–25 trough becomesnorm (40%)Self-help competed away(30%)ME de-escalation resetsPE (35%)Sadara guarantee called(20%)Rates keep housing weak(40%)−$16.04−$6.61−$1.29−$0.40−$0.21

Source: Penmark Research model (unweighted $/sh).

What would end our thesis ($16.20/sh bear case)

Our Buy thesis breaks if Chinese ethylene self-sufficiency and stalled European closures lock global operating rates in the low 80s permanently. Because $25.3bn of debt, minority, pension and legacy claims sit ahead of common equity, cutting historical through-cycle margin from 14.8% to 11.0% with the self-help credit unchanged (−$1.7bn normalised EBITDA) wipes out $16.04/sh of equity value, pulling full-model Bear value down to $16.20/sh (−47%).

Exhibit 79: Downside risk register: operating, balance-sheet, legal, key-person & value-relevant ESG risks
Risk factor Prob. Model shock Value /sh Mechanism, filing evidence & mitigation
FY23–25 overbuild becomes new mid-cycle40%−$1,729m norm. EBITDA−$16.04New Chinese crackers & restarted JVs prevent 10% capacity exit; historical margin reverts to 11.0% (vs 14.8% history), credit held.
T2O self-help competed away30%−$390m FY27E; 0% mid-cycle−$6.612023 & 2025 $1bn cost programmes coincided with falling margins; FY27E realisation drops from 85% to 55% and mid-cycle retention falls to 0%.
Middle East de-escalation resets PE35%−$1,200m FY27E (−10¢/lb)−$1.29Unwinding 2026 shipping/oil disruption compresses oil-to-gas spread; cuts near-term FCF, though mid-cycle multiple buffers EV.
Higher-for-longer rates & housing40%−$200m FY27E MDI−$0.215.15%+ 10Y US Treasury yields suppress housing turnover and appliances (40% of MDI demand).
Discount-rate / WACC shock (+1pt)Sens.WACC 7.3% → 8.3%−$10.91 targetLifting WACC +100bp cuts our rolled 12-month target from $37.84 to $26.93 (−6.7% total return, Hold).
Sadara debt guarantee called20%+$292m EV bridge claim−$0.40Creditors call Dow’s share of project guarantees plus interest ($1,550m bear vs $1,258m recorded in 3Q26 10-Q).
Environmental & asbestos escalationMed.Up to ~2.5x $991m accrualUp to ~−$1.533Q26 10-Q Note 12 flags environmental remediation up to ~2.5x accrued as reasonably possible (~$1.1bn after-tax unmodelled).
Path2Zero capex / carbon-policy ESGMed.$4.1bn capex / $0.9bn APIPUp to −$2.22Bear case ($700m run-rate EBITDA vs $1.0bn) cuts Path2Zero NPV from $2.7bn to $1.1bn (−$1.6bn) if build overruns >20% (~$8.3bn) or credits weaken.
CEO transition & 4,500-role cutsLow–Med.Operational / reliabilityQualitativeKaren S. Carter became CEO on 1 Jul 2026 while cutting 4,500 roles (~70% done); cracker outages or safety incidents hurt volume.

Source: FY25 Form 10-K Item 1A and 3Q26 Form 10-Q Notes 9, 12 & 19; Penmark Research model.

Leverage & dividend vulnerability in a prolonged trough: Dow holds ~$14bn of committed liquidity and faces no material long-term debt maturities until 2029. However, in our Bear case ($4.6bn FY27E Op. EBITDA, $0.83 Op. EPS), free cash flow barely covers the $1.0bn common dividend ($1.40/sh) plus $0.3bn NCI distributions while funding $1.2bn of Path2Zero capex. That revives dividend-cut risk if trough spreads persist past 2027.
PART 4 · THE NUMBERS · 18 OWNERSHIP, SHORT INTEREST AND TRADING

Institutions hold 76% of shares, short interest fell 27% since August, and 75% of the Street rates Hold or Sell

Exhibit 80: Short interest fell 27% to 27.5m shares (30 Oct 26)
20m25m30m35m40mJun-26Jul-26Aug-26Sep-26Oct-2627.5m

Source: Exchange bi-weekly short-interest settlements (May–Oct 2026).

Exhibit 81: Our $38 target sits above the $33 October Street mean ($29–$41)
Street low $29.00Street median $32.00Penmark target $37.84Price $30.37Street mean (Oct) $33.29Street high $41.00

Source: S&P Global (20 analysts, Oct 2026); Penmark Research.

Trading liquidity, index status & Street split

Liquidity & indexes: Dow trades 8.56m shares/day ($260.9m 3M average daily trading value [ADTV], Yahoo Finance) with 99.5% public float (723.9m basic shares; zero lock-ups; 68.1m treasury shares) and sits in the S&P 500 and Materials Select Sector (XLB) indexes.
Street skew: Across the 20 analysts in the October 2026 S&P Global set, only 5 rate Buy vs 13 Hold and 2 Sell (mean target $33.29; median $32.00; range $29–$41; 3-month revision trend down).

Exhibit 82: Top 10 13F holders own 43% of shares; 1,159 institutions hold 76% at 30 Sep 2026
Reported 13F institution 3Q26 shares % of basic sh 3Q26 value ($m) Reported q/q sh change Reported q/q %
The Vanguard Group90,113,89312.45%2,481.7+565,074+0.63%
BlackRock, Inc.57,873,8518.00%1,593.8−3,868,729−6.27%
State Street Corp.38,787,4175.36%1,068.2+918,007+2.42%
AQR Capital Management29,504,6324.08%812.0+13,806,393+87.95%
Geode Capital Management20,086,0612.77%553.2+804,694+4.17%
Capital World Investors20,039,0522.77%551.9+4,294,552+27.28%
Two Sigma Investments19,243,2622.66%530.0+1,369,896+7.66%
Morgan Stanley14,232,0671.97%392.0−867,699−5.75%
Pzena Investment Management11,904,7751.64%327.9−602,236−4.82%
Invesco Ltd.11,599,9011.60%319.5+1,930,697+19.97%
Total 13F filers (1,159 institutions)549,300,42475.88%15,127.7−12,117,051−2.16%

Source: Form 13F filings for quarters ended 30 Jun 2026 and 30 Sep 2026 (723.882m shares outstanding at 30 Sep 2026; values at $27.54 quarter-end close).

Interpreting 13F & Form 4 filings carefully: Quarterly Form 13F snapshots report US long equity positions with a 45-day lag and do not separate passive fund flows, index reweights or multi-strategy hedging from active conviction changes; a single-quarter reported shift should not be read as discretionary institutional selling or exits. Similarly, CFO Jeffrey L. Tate’s 26 Oct 2026 Form 4 (25,564 shares at $33.99; 93,197 shares retained) was a code-D disposition to the issuer (tax withholding on vesting), not an open-market sale, while CEO Karen S. Carter received July 2026 promotion equity grants (24,150 shares plus 126,640 derivative/option awards). Short covering (37.5m shares on 14 Aug to 27.5m on 30 Oct, 3.0 days to cover) coincided with Q3’s beat.
PART 5 · APPENDIX · 19 FINANCIAL MODEL: ANNUAL STATEMENTS AND RATIOS

The model reaches $8.0bn of EBITDA in FY30E and $9.4bn in FY35E

Exhibit 83: Annual operating & GAAP income statement (FY24A–FY30E and FY35E, US$m)
Income statement FY24AFY25AFY26EFY27EFY28EFY29EFY30EFY35E
Existing-assets net sales42,96439,96844,03343,11543,97744,85745,75450,516
Alberta Path2Zero net sales0000009602,400
Consolidated net sales42,96439,96844,03343,11543,97744,85746,71452,916
Existing-assets Op. EBITDA5,4823,2566,2886,4346,8177,2147,6248,417
Alberta Path2Zero Op. EBITDA0000004001,000
Consolidated Operating EBITDA5,4823,2566,2886,4346,8177,2148,0249,417
Depreciation & amortisation−2,894−2,834−2,719−2,726−2,717−2,721−2,730−3,055
Operating EBIT2,5884223,5693,7074,1004,4935,2936,362
Net interest (income less expense)−611−713−670−667−640−672−720−833
Operating tax (22% E) & NCI−771−371−932−969−1,061−1,141−1,306−1,516
Operating net income to Dow1,206−6621,9672,0722,3992,6803,2674,013
GAAP / post-restructuring net income1,116−2,6239821,6232,2822,6023,2674,013

Source: FY24–FY25 Form 10-K; Penmark Research model (FY31E–34E omitted for width; full 10y DCF in Exhibit 74).

Exhibit 84: Annual cash flow & balance-sheet summary (FY24A–FY30E and FY35E, US$m)
Cash flow & balance sheet FY24AFY25AFY26EFY27EFY28EFY29EFY30EFY35E
Cash from operations (continuing)2,9141,0625,4634,6185,1485,4705,9727,194
Capital expenditures (incl. Alberta)−2,940−2,479−2,501−2,650−2,750−2,800−2,575−4,158
Free cash flow (FCF)−26−1,4172,9621,9682,3982,6703,3973,036
Dividends to Dow & NCI−1,966−1,490−1,315−1,316−1,310−1,379−1,506−2,092
Share buybacks−49400−230−1,088−1,290−1,891−945
Cash & equivalents2,1893,8164,1333,3003,3003,3003,3003,300
Trade working capital6,4537,2067,5147,5457,6967,8508,1759,260
Net property (PP&E)22,00422,25022,42822,49922,66122,85522,80227,244
Gross debt16,34318,16117,33916,08416,08416,08416,08416,084
Net debt ($m)14,15414,34513,20612,78412,78412,78412,78412,784
Dow Inc. stockholders’ equity17,35516,00816,23416,61116,79517,02717,19722,366

Source: FY24–FY25 Form 10-K; Penmark Research model.

Exhibit 85: Per-share data, operating returns & leverage ratios (FY24A–FY30E and FY35E)
Per-share & ratio summary FY24AFY25AFY26EFY27EFY28EFY29EFY30EFY35E
Weighted diluted shares (m)705.1711.6725.5721.8696.4667.7627.6516.5
Operating diluted EPS ($/sh)1.71−0.932.712.873.444.015.217.77
Dividend per share ($/sh)2.802.101.401.401.401.551.813.37
Free cash flow per share ($/sh)−0.04−1.994.082.733.444.005.415.88
Operating ROE (avg equity)6.7%−4.0%12.2%12.6%14.4%15.9%19.1%18.5%
Operating ROA (net assets)3.1%−1.7%4.9%5.3%6.2%6.9%8.4%9.2%
After-tax operating ROIC / ROCE6.3%1.0%9.0%9.4%10.3%11.2%13.1%13.5%
Net debt / Operating EBITDA2.58x4.41x2.10x1.99x1.88x1.77x1.59x1.36x
Gross debt / Operating EBITDA2.98x5.58x2.76x2.50x2.36x2.23x2.00x1.71x

Source: Company filings; Penmark Research model (dividend rule: $1.40/sh floor or 45% of prior-year Op. EPS).

Balance-sheet & capital-return rules: Gross debt steps down to $16.1bn in FY27E under our 2.5x gross leverage rule with a $3.3bn minimum cash floor. Above that threshold, excess FCF funds share buybacks priced at the higher of share price and base value, rolled at cost of equity less dividend yield; dividend per share rises above $1.40 from FY29E ($1.55/sh) under the 45% payout rule.
PART 5 · APPENDIX · 19 FINANCIAL MODEL: QUARTERLY TRAJECTORY, SEGMENTS AND KPIS

P&SP drives 68% of FY26E operating EBITDA as Dow completes a $6.3bn rebound year

Exhibit 86: Quarterly reported trajectory, 4Q26E & FY26E–FY27E annual anchor (US$m except EPS)
Quarterly & annual path 1Q25A2Q25A3Q25A4Q25A1Q26A2Q26A3Q26A4Q26EFY26EFY27E
P&SP net sales5,3105,0254,8914,7444,9196,3855,7785,80022,88221,939
II&I net sales2,8552,7862,8342,6882,6263,1663,0582,85011,70011,462
PM&C net sales2,0712,1292,0821,8522,0802,3612,2502,0508,7419,003
Corporate net sales195164166176169180181180710710
Consolidated net sales10,43110,1049,9739,4609,79412,09211,26710,88044,03343,115
P&SP Operating EBITDA7024405485765901,6399541,0804,2634,107
II&I Operating EBITDA18−32111−36303833232509861,022
PM&C Operating EBITDA2493442541992982912992601,1481,424
Corporate Operating EBITDA−25−49−452−45−1−23−40−109−120
Consolidated Op. EBITDA9447038687418732,3121,5531,5506,2886,434
Operating EBITDA margin9.0%7.0%8.7%7.8%8.9%19.1%13.8%14.2%14.3%14.9%
Operating diluted EPS ($/sh)0.02−0.42−0.19−0.34−0.141.440.710.682.712.87
Local price / Volume y/y−3%/+2%−7%/−1%−8%/−1%−8%/−2%−7%/−2%n.a./−1%+14%/−1%n.a.n.a.−4%/+2%

Source: Company quarterly releases and 3Q26 Form 8-K; Penmark Research model (n.a. = not available).

Exhibit 87: Multi-year segment sales, Operating EBITDA, margins & archetype KPIs (FY22A–FY27E)
Segment & operating KPIs FY22AFY23AFY24AFY25A9M26AFY26EFY27E
Segment net sales ($m)
Packaging & Specialty Plastics29,26023,14921,77619,97017,08222,88221,939
Industrial Intermediates & Infrastr.16,60612,53811,86911,1638,85011,70011,462
Performance Materials & Coatings10,7648,4978,5748,1346,6918,7419,003
Consolidated net sales (incl. Corp.)56,90244,62242,96439,96833,15344,03343,115
Segment Operating EBITDA ($m) and margin (%)
Packaging & Specialty Plastics5,506 (18.8%)3,985 (17.2%)3,856 (17.7%)2,266 (11.3%)3,183 (18.6%)4,263 (18.6%)4,107 (18.7%)
Industrial Intermediates & Infrastr.1,968 (11.9%)648 (5.2%)724 (6.1%)61 (0.5%)736 (8.3%)986 (8.4%)1,022 (8.9%)
Performance Materials & Coatings2,117 (19.7%)997 (11.7%)1,094 (12.8%)1,046 (12.9%)888 (13.3%)1,148 (13.1%)1,424 (15.8%)
Consolidated Op. EBITDA (incl. Corp.)9,348 (16.4%)5,389 (12.1%)5,482 (12.8%)3,256 (8.1%)4,738 (14.3%)6,288 (14.3%)6,434 (14.9%)
Archetype operating KPIs (Products & units, cyclical)
USGC / Global Hydrocarbons op. raten.a.n.a.n.a.Low 80s>90% / 83%>90% / ~83%>90% / n.a.
Incremental T2O / self-help ($m)n.a.n.a.n.a.400~5007001,105 (85%)
Cash conversion (CFO / Op. EBITDA)n.a.96.4%53.2%32.6%90.5%86.9%71.8%
Trade working capital % of sales13.5%14.0%15.0%18.0%17.9%17.1%17.5%

Source: FY25 Form 10-K Note 24 and 3Q26 release; Penmark Research model (Corporate EBITDA: −$243m / −$241m / −$192m / −$117m / −$69m / −$109m / −$120m).

Segment mix & cyclical damping: P&SP accounts for 52% of FY26E sales and 68% of FY26E Operating EBITDA ($4.3bn), making integrated ethylene-to-polyethylene spreads the main earnings swing factor. PM&C’s steadier downstream silicones and coatings margin (13%–16% across FY24A–FY27E, helped by shutting high-cost Barry upstream siloxanes in 2Q26) and T2O’s 25%/25% allocation to II&I and PM&C cushion FY27E consolidated EBITDA even as PE fades −4¢/lb.
PART 5 · APPENDIX · 20 REFERENCE: RECONCILIATION, GLOSSARY AND METHODOLOGY

GAAP-to-operating reconciliation, ratio definitions, cyclical methodology and data cut-off

Exhibit 88: Reconciliation of GAAP reported figures to Operating EBITDA, Operating Net Income & FCF (US$m)
GAAP-to-non-GAAP reconciliation FY24AFY25A9M26AFY26EFY27EFY28E
GAAP net income / (loss) attributable to Dow Inc.1,116−2,6236469821,6232,282
Exclude: Significant items / after-tax restructuring901,961829985449117
Operating net income attributable to Dow Inc.1,206−6621,4751,9672,0722,399
Operating EBIT (segment sum, ex-significant items)2,5884222,6893,5693,7074,100
Add: Depreciation and amortisation (D&A)2,8942,8342,0492,7192,7262,717
Operating EBITDA5,4823,2564,7386,2886,4346,817
Free cash flow (continuing CFO less total capex)−26−1,4172,4462,9621,9682,398

Source: FY25 Form 10-K, 3Q26 Form 8-K/10-Q; Penmark Research model.

Glossary of company & sector terms

Integrated PE margin (¢/lb): Margin per pound captured by cracking NGLs/naphtha into ethylene and polymerising into polyethylene; ~±$200m annual Dow EBITDA per ±1¢/lb.

Ethane advantage: Cost spread of US/Canadian natural-gas-derived ethane crackers (~25–28¢/gal) beneath European and Asian crude-oil-linked naphtha crackers.

MDI & alkoxylates: Methylene diphenyl diisocyanate (rigid/flexible polyurethane foams; ~40% housing-exposed) and specialty surfactants in II&I.

Siloxanes vs silicones: Upstream commodity siloxane monomers (oversupplied in China; Barry UK shut 2Q26) vs higher-margin downstream formulated silicones in PM&C.

Transform to Outperform (T2O): Restructuring programme (~4,500 roles, AI/automation & commercial growth) targeting ~$2.0bn EBITDA uplift by end-2027 ($0.7bn FY26, $1.2bn FY27 plus $0.1bn asset actions).

Path2Zero & APIP: Fort Saskatchewan, Alberta net-zero ethylene/PE expansion ($7.5bn gross capex, $6.2bn net after Alberta Petrochemicals Incentive Program [APIP] grants of about C$1.8bn [US$1.3bn], ~45% built; $1.0bn run-rate EBITDA by FY32E).

Sadara: 35%-owned Saudi petrochemical JV with Aramco; equity losses suspended 1Q26; $1,258m recorded negative investment & debt guarantee deducted in EV bridge.

Peer set

Primary valuation peer set: LyondellBasell (LYB, closest integrated polyolefins peer and 6.74x 13-year median EV/EBITDA anchor), Westlake (WLK), Eastman Chemical (EMN), Celanese (CE) and Huntsman (HUN). Global uncovered competitors (BASF, Covestro, Wacker, SABIC, Sinopec) are included in cost-curve, competitive and regression exhibits.

Ratio & valuation definitions

Operating EBITDA & FCF: Operating EBIT (ex-significant items, after operating lease expense) plus D&A; FCF = continuing CFO less total capital expenditures (one basis: deferred revenue $199m at Sep-26).

Operating ROE / ROA / ROIC (ROCE): Operating net income to Dow ÷ average stockholders’ equity (ROE); Operating net income to Dow ÷ average net invested assets (ROA); Operating EBIT × (1 − 22% op. tax) ÷ ending invested capital (equity + NCI + debt − cash).

EV definition: Full-bridge EV at $30.37 ($45,389m, used for all current multiples) = diluted market cap ($22,091m on 727.4m diluted shares; $21,984m basic) + net debt ($13,397m) + NCI at market ($3,439m = $2,943m InfraCo 49% + $496m book) + after-tax pension ($3.2bn), Sadara ($1.3bn), env./asbestos ($1.2bn) & remaining cash restructuring ($0.8bn), excluding the $2.0bn recovery-path wait-cost charge (present value of the after-tax profit shortfall below mid-cycle, 4Q26E to FY30E).

Methodology, situations & known limits

Archetype & situations: Products & units, cyclical, with leveraged/legacy-claims equity bridge and restructuring add-ons; ten-year explicit forecast to FY35E.

Conviction rating: Conviction is Low because lifting WACC by +1pt flips the rating to Hold ($26.93 target) and global-chemical high-end levered beta (1.60x) flips it to Sell ($24.31 target).

Limits & sources (cut-off 20 Nov 2026): Official close $30.37 (18 Nov 2026; 19 Nov $30.26 last trade not official close, −0.4%); SEC filings (FY25 10-K 3 Feb 26, DEF 14A 27 Feb 26, 3Q26 8-K/10-Q 22–23 Oct 26, Form 13F 30 Sep 26, Form 4 through Nov 26); exchange short interest (30 Oct 26); S&P Global consensus (Oct 2026); Yahoo Finance price/return series; environmental accrual could reach ~2.5x; $3.2bn other investments (insurance) conservatively excluded.

PART 5 · APPENDIX · 21 DISCLOSURES

Analyst certification and important disclosures

Ratings

Ratings are based on the total return from the share price to our 12-month price target, including dividends. The price target is weighted across bull, base and bear scenarios.

BuyTotal return to price target above +10%
HoldTotal return to price target from −10% to +10%, inclusive
SellTotal return to price target below −10%

We review ratings at each set of results and whenever the facts change materially. A share price can move outside its band before the rating changes, and targets may not be reached.

Analyst certification

The Penmark Team certifies that (1) the views in this report accurately reflect its views about the subject company and its securities, and (2) no part of its compensation was, is or will be directly or indirectly related to the specific ratings, price targets or views in this report.

Contact

Penmark Research

Questions about our research:
research@penmarkresearch.com

All our research and coverage:
penmarkresearch.com

Basis of preparation

This report uses information publicly available up to its publication date. Share prices are closing prices on the trading day before the publication date, unless stated otherwise. Forecasts, valuations and price targets are Penmark Research’s own, and forecast periods are marked E. Sources are shown beneath each exhibit.

Valuation and price targets

Price targets are based on the valuation methods set out in each report and are weighted across bull, base and bear scenarios. The main risks to each rating and price target are described in the report. Penmark Research updates its coverage after each set of results but is not obliged to update a report at any other time.

Independence and conflicts of interest

Penmark Research is independent. It does not provide investment banking, brokerage, market-making or asset management services, does not trade securities, and does not accept payment from any company for research coverage. Companies do not see or review Penmark Research reports before publication.

No member of the Penmark Team holds a long or short position, directly or through derivatives, in the securities of any company Penmark Research covers.

Regulatory status

Penmark Research publishes general, impersonal investment research on a regular basis. It is not registered as an investment adviser with the US Securities and Exchange Commission or any state securities authority, is not a registered broker-dealer and is not a member of FINRA. Penmark Research does not give advice tailored to any person’s circumstances.

Not investment advice or an offer

This report is for information only. It is not personalised investment advice and is not an offer or solicitation to buy or sell any security or other financial instrument. It does not take into account any reader’s objectives, financial situation or needs. Readers should make their own investment decisions and seek independent professional advice where appropriate.

Forward-looking statements and risk

Forecasts, valuations and price targets are estimates based on assumptions that may prove wrong, and they may not be achieved. Opinions are current as of the publication date and may change without notice. Investing in equities involves risk, including the loss of capital. Share prices can be volatile, and past performance is not a reliable indicator of future results.

Data and sources

Company financials, operating data and filings come from company filings, earnings releases and earnings calls. Market data and any consensus estimates come from third-party sources named beneath the relevant exhibit; consensus figures from aggregators are unofficial. Penmark Research does not use other brokers’ research. Third-party data belong to their providers and may not be extracted from this report.

Accuracy and liability

Information is taken from sources believed to be reliable, but Penmark Research makes no representation or warranty as to its accuracy, completeness or timeliness. To the fullest extent permitted by law, Penmark Research accepts no liability for any loss arising from use of this report. Descriptions of litigation and regulatory matters reflect allegations and public records, not findings, unless stated. If a published report is corrected, the corrected version carries an “Updated” date at penmarkresearch.com.

Distribution and access

Penmark Research reports are available to registered users of penmarkresearch.com. Downloads and programmatic access are governed by the Penmark Research subscription terms. This report is not directed at, or intended for, any person in Singapore or India, and access from those countries is blocked. It is not intended for distribution to, or use by, any person in any jurisdiction where that would be contrary to law or regulation or would subject Penmark Research to registration or licensing requirements there.

Copyright and permitted use

© Penmark Research. All rights reserved. Penmark Research is a trade name of Brightriver Labs. Readers may share a link to this report but may not copy, reproduce, redistribute, sell or use its content, including for text and data mining, without written consent. Contact: research@penmarkresearch.com.

Sign in to Penmark